<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">EBM</journal-id>
<journal-id journal-id-type="hwp">spebm</journal-id>
<journal-title>Experimental Biology and Medicine</journal-title>
<issn pub-type="ppub">1535-3702</issn>
<issn pub-type="epub">1535-3699</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1535370212473704</article-id>
<article-id pub-id-type="publisher-id">10.1177_1535370212473704</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Minireviews</subject>
<subj-group subj-group-type="heading">
<subject>Cell and Developmental Biology</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Diabetic complications in pregnancy: is resveratrol a solution?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Singh</surname><given-names>Chandra K</given-names></name>
<xref ref-type="aff" rid="aff1-1535370212473704">1</xref>
<xref ref-type="aff" rid="aff2-1535370212473704">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kumar</surname><given-names>Ambrish</given-names></name>
<xref ref-type="aff" rid="aff1-1535370212473704">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>LaVoie</surname><given-names>Holly A</given-names></name>
<xref ref-type="aff" rid="aff3-1535370212473704">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>DiPette</surname><given-names>Donald J</given-names></name>
<xref ref-type="aff" rid="aff3-1535370212473704">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Singh</surname><given-names>Ugra S</given-names></name>
<xref ref-type="aff" rid="aff1-1535370212473704">1</xref>
<xref ref-type="corresp" rid="corresp1-1535370212473704"/>
</contrib>
</contrib-group>
<aff id="aff1-1535370212473704"><label>1</label>Department of Pathology, Microbiology and Immunology, School of Medicine, 6311 Garners Ferry Road, Columbia SC 29209</aff>
<aff id="aff2-1535370212473704"><label>2</label>Department of Dermatology, University of Wisconsin, Madison WI 53706</aff>
<aff id="aff3-1535370212473704"><label>3</label>Department of Cell Biology and Anatomy, School of Medicine, University of South Carolina, Columbia SC 29209, <country>USA</country></aff>
<author-notes>
<corresp id="corresp1-1535370212473704">Ugra S Singh. Email: <email>Ugra.Singh@uscmed.sc.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2013</year>
</pub-date>
<volume>238</volume>
<issue>5</issue>
<issue-title>Mini-Review Annual Issue</issue-title>
<fpage>482</fpage>
<lpage>490</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013 by the Society for Experimental Biology and Medicine</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="society">The Society for Experimental Biology and Medicine</copyright-holder>
</permissions>
<abstract>
<p>Diabetes is a metabolic disorder that, during pregnancy, may affect fetal development. Fetal outcome depends on the type of diabetes present, the concentration of blood glucose and the extent of fetal exposure to elevated or frequently fluctuating glucose concentrations. The result of some diabetic pregnancies will be embryonic developmental abnormalities, a condition referred to as diabetic embryopathy. Tight glycemic control in type 1 diabetes during pregnancy using insulin therapy together with folic acid supplementation are partially able to prevent diabetic embryopathy; however, the protection is not complete and additional interventions are needed. Resveratrol, a polyphenol found largely in the skins of red grapes, is known to have antidiabetic action and is in clinical trials for the treatment of diabetes, insulin resistance, obesity and metabolic syndrome. Studies of resveratrol in a rodent model of diabetic embryopathy reveal that it significantly improves the embryonic outcome in terms of diminishing developmental abnormalities. Improvements in maternal and embryonic outcomes observed in rodent models may arise from resveratrol's antioxidative potential, antidiabetic action and antidyslipidemic nature. Whether resveratrol will have similar actions in human diabetic pregnancy is unknown. Here, we review the potential therapeutic use of resveratrol in diabetes and diabetic pregnancy.</p>
</abstract>
<kwd-group>
<title>Keywords</title>
<kwd>diabetic pregnancy</kwd>
<kwd>neural tube defects</kwd>
<kwd>resveratrol</kwd>
<kwd>hyperglycemia</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1" sec-type="intro">
<title>Introduction</title>
<p>Diabetes is a metabolic disease in which high blood-glucose concentrations exist either because the body does not produce sufficient insulin (type 1 diabetes) or because cells fail to properly respond to insulin (type 2 diabetes).<sup><xref ref-type="bibr" rid="bibr1-1535370212473704">1</xref></sup> A third kind of diabetes, known as gestational diabetes, occurs when a pregnant woman develops high blood-glucose levels typically during the second half of pregnancy due to the hormones of pregnancy.<sup><xref ref-type="bibr" rid="bibr2-1535370212473704">2</xref></sup> Gestational diabetes can revert to normal following pregnancy, but sometimes precedes the development of type 2 diabetes. Recent data of the National Diabetes Fact Sheet shows that total 25.8 million children and adults in the USA (8.3% of the population) have diabetes (Centers for Disease Control and Prevention, 2011; <uri xlink:href="http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf">http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf</uri>).<sup><xref ref-type="bibr" rid="bibr3-1535370212473704">3</xref></sup> All forms of diabetes increase the risk of long-term complications. Up to 67% of adults with diabetes have high blood pressure.<sup><xref ref-type="bibr" rid="bibr3-1535370212473704">3</xref></sup> Long-term diabetes damages blood vessels. Diabetics have double the risk of heart attack or stroke. Diabetes causes nerve damage in the heart, which can make a heart attack painless or ‘silent,’ and affects blood vessel formation in the retina of the eye, leading to visual symptoms and sometimes blindness (diabetic retinopathy).<sup><xref ref-type="bibr" rid="bibr1-1535370212473704">1</xref>,<xref ref-type="bibr" rid="bibr3-1535370212473704">3</xref></sup> High blood sugar can lead to scarring of kidney tissues that may result in chronic kidney diseases (diabetic nephropathy). Diabetes also affects the nervous system (diabetic neuropathy), causing numbness, tingling and pain in the feet, and increasing the risk of skin damage because of altered sensation.<sup><xref ref-type="bibr" rid="bibr1-1535370212473704">1</xref>,<xref ref-type="bibr" rid="bibr3-1535370212473704">3</xref></sup> As diabetes affects every part of the body, it can also have devastating complications to the mother and embryo.</p>
</sec>
<sec id="sec2">
<title>Diabetic pregnancies are a serious concern</title>
<p>The incidence of diabetes mellitus and its sequelae is rising in the general population, and it is an additional risk factor in pregnancy, causing birth defects commonly referred to as diabetic embryopathies. Although most embryonic organs are affected by maternal diabetes, the central nervous system is comparatively more susceptible to high glucose.<sup><xref ref-type="bibr" rid="bibr4-1535370212473704">4</xref>–<xref ref-type="bibr" rid="bibr13-1535370212473704">13</xref></sup> Among the various malformations in diabetic embryopathy, neural tube defects (NTDs) are one of the most common.<sup><xref ref-type="bibr" rid="bibr5-1535370212473704">5</xref>,<xref ref-type="bibr" rid="bibr14-1535370212473704">14</xref>–<xref ref-type="bibr" rid="bibr16-1535370212473704">16</xref></sup> Although the incidence of NTDs in diabetic pregnancies has been reduced by intensive insulin treatment and glucose monitoring, they are still 2- to 6-fold greater than in normal pregnancies.<sup><xref ref-type="bibr" rid="bibr17-1535370212473704">17</xref>–<xref ref-type="bibr" rid="bibr19-1535370212473704">19</xref></sup> Folic acid consumption alone or in combination with vitamin E diminishes the diabetes-induced embryonic malformations in diabetic pregnancy.<sup><xref ref-type="bibr" rid="bibr20-1535370212473704">20</xref>–<xref ref-type="bibr" rid="bibr22-1535370212473704">22</xref></sup> Currently, folic acid supplementation is standard practice to avoid birth defects, but the protection afforded by folic acid supplementation against diabetes-induced birth defects is not enough. Approximately 50% of congenital malformations can be prevented if folic acid is supplemented before and during pregnancy.<sup><xref ref-type="bibr" rid="bibr23-1535370212473704">23</xref>–<xref ref-type="bibr" rid="bibr25-1535370212473704">25</xref></sup> The folic acid tolerable intake limit is thought to be 1 mg/day; however, a few studies advocate the use of high-dose folic acid (4–5 mg/day) during diabetic pregnancy.<sup><xref ref-type="bibr" rid="bibr26-1535370212473704">26</xref></sup> Folate is needed for DNA synthesis but can also serve as a methyl group donor for DNA methylation, and thereby alter the embryo's epigenome by epigenetic modification of DNA.<sup><xref ref-type="bibr" rid="bibr27-1535370212473704">27</xref></sup> Recently, DNA methylation by folate and the C677T mutation of the enzyme methylenetetrahydrofolate reductase (MTHFR), and thereby impaired MTHFR function have been shown as one of the cause of recurrent fetal loss and potential factor in the etiology of autism.<sup><xref ref-type="bibr" rid="bibr28-1535370212473704">28</xref>,<xref ref-type="bibr" rid="bibr29-1535370212473704">29</xref></sup> There are currently no drugs or nutritional supplements available for complete protection against embryonic malformation during diabetic pregnancy, and NTDs and other birth defects are still a serious concern in diabetic pregnancies. These gaps in knowledge provide a compelling reason to further investigate alternative options for the prevention of neural tube defects in diabetic pregnancies.</p>
</sec>
<sec id="sec3">
<title>Resveratrol, a grape antioxidant, and prevention of diabetic embryopathy</title>
<p>Recent studies have demonstrated that resveratrol (<italic>trans</italic>-3,5,4′-trihydroxystilbene), found in red grapes and blueberries, lowers maternal blood sugar, improves maternal lipid profile<sup><xref ref-type="bibr" rid="bibr30-1535370212473704">30</xref></sup> and prevents developmental delays in embryos of rat diabetic dams.<sup><xref ref-type="bibr" rid="bibr31-1535370212473704">31</xref></sup> On the basis of these results, resveratrol could be a potential therapeutic agent for the prevention of embryonic malformations including NTDs.<sup><xref ref-type="bibr" rid="bibr31-1535370212473704">31</xref></sup> Our understanding of the signaling mechanisms involved in diabetes mellitus has progressed greatly, but very little is known about the mechanism(s) underlying NTDs in diabetic pregnancy. Further studies are needed to determine whether the combined effects of resveratrol and folic acid can completely abolish the birth defects in diabetic pregnancies. Here, we review the literature and provide some new insights to aid further understanding of the signaling mechanisms associated with NTDs and how resveratrol may prevent these defects.</p>
<p>Various plants produce resveratrol to help defend against invading fungi, stress, injury, infection and excessive sunlight. Resveratrol is found in both <italic>cis-</italic> and <italic>trans</italic>-stereoisomeric forms existing as a glucoside (bound to a glucose molecule). The roots of the plant <italic>Polygonum cuspidatum</italic> (KO-jo-kon), mainly cultivated in Asia, provides a rich source of resveratrol from which commercially available <italic>trans</italic>-resveratrol (&gt;98% pure) is isolated by high-speed counter-current chromatography.<sup><xref ref-type="bibr" rid="bibr32-1535370212473704">32</xref></sup> Resveratrol has been reported to possess many salutary effects, including cardioprotection,<sup><xref ref-type="bibr" rid="bibr33-1535370212473704">33</xref></sup> chemoprevention,<sup><xref ref-type="bibr" rid="bibr34-1535370212473704">34</xref>,<xref ref-type="bibr" rid="bibr35-1535370212473704">35</xref></sup> and extension of lifespan in several species.<sup><xref ref-type="bibr" rid="bibr36-1535370212473704">36</xref>,<xref ref-type="bibr" rid="bibr37-1535370212473704">37</xref></sup> However, the molecular mechanisms underlying the resveratrol functions are different in different diseases. Resveratrol has been in use since ancient times as an herbal formulation termed ‘Darakchasava.’ The ancient medicinal book of Hindus, <italic>Ayurveda</italic>, more than 4500 years ago described Darakchasava, a heart tonic made from fermented grapes. The formulation is believed to counteract lethargy, weakness and heat exhaustion and stimulate cardiac function. Darakchasava is also thought to have antipyretic, diuretic and diaphoretic effects. Today, Darakchasava contains 1.3–6.0 mg/L of resveratrol, depending on the pharmaceutical company producing it.<sup><xref ref-type="bibr" rid="bibr38-1535370212473704">38</xref></sup></p>
<p>Managing diabetes is one of modern medicine's major challenges, and it remains one of the leading causes of morbidity and mortality among tens of millions of people in the USA alone. Resveratrol has shown promising results in the management of diabetes. In diet-induced obese and diabetic mice, long-term intracerebroventricular infusion of resveratrol corrects hyperglycemia and improves hyperinsulinemia.<sup><xref ref-type="bibr" rid="bibr39-1535370212473704">39</xref></sup> In high-fat-diet-fed mice, it ameliorates insulin resistance, increases the mitochondrial content of cells and prolongs survival.<sup><xref ref-type="bibr" rid="bibr40-1535370212473704">40</xref></sup> Resveratrol has beneficial effects on dyslipidemia and obesity. In another study, resveratrol demonstrated significant antihyperglycemic activity, improving insulin levels and oral glucose tolerance tests in <italic>ob/ob</italic> mice.<sup><xref ref-type="bibr" rid="bibr41-1535370212473704">41</xref></sup> Resveratrol action has been linked to the activation of a histone deacetylase Sirtuin 1 (Sirt1).<sup><xref ref-type="bibr" rid="bibr40-1535370212473704">40</xref>,<xref ref-type="bibr" rid="bibr41-1535370212473704">41</xref></sup> Administration of resveratrol to diabetic rats results in a significant decrease in blood-glucose concentrations, glycosylated hemoglobin, blood urea and other blood compounds that are usually elevated in type II diabetes and cause damage to body organs.<sup><xref ref-type="bibr" rid="bibr39-1535370212473704">39</xref>,<xref ref-type="bibr" rid="bibr42-1535370212473704">42</xref></sup> During starvation or limited food, Sirt1 promotes the breakdown of fat stores as a source of energy. Sirt1 is activated through caloric restriction and lengthens rodent lifespan and improves overall health by aiding fat metabolism, increasing immune function, and boosting cardiovascular health.<sup><xref ref-type="bibr" rid="bibr43-1535370212473704">43</xref></sup> Notably, when Sirt1 is activated by resveratrol, diabetes is improved.<sup><xref ref-type="bibr" rid="bibr41-1535370212473704">41</xref></sup></p>
<p>Resveratrol also activates the 5′-AMP-activated protein kinase (AMPK), which also regulates insulin sensitivity and mitochondrial biogenesis.<sup><xref ref-type="bibr" rid="bibr43-1535370212473704">43</xref></sup> The net effect of AMPK activation is stimulation of hepatic fatty-acid oxidation and ketogenesis; increase of skeletal muscle fatty acid oxidation and muscle glucose uptake; inhibition of cholesterol synthesis, lipogenesis, triglyceride synthesis, adipocyte lipolysis; and modulation of insulin secretion by pancreatic beta-cells. In mice deficient in the catalytic subunit of AMPK (α1 or α2), resveratrol fails to increase insulin sensitivity, glucose tolerance, mitochondrial biogenesis and physical endurance,<sup><xref ref-type="bibr" rid="bibr44-1535370212473704">44</xref></sup> indicating the necessity of AMPK in multiple resveratrol-mediated effects.</p>
</sec>
<sec id="sec4">
<title>Resveratrol is safe, but its bioavailability is poor</title>
<p>Resveratrol use in humans has no pronounced toxicity,<sup><xref ref-type="bibr" rid="bibr45-1535370212473704">45</xref></sup> and orally administered <italic>trans</italic>-resveratrol is well-absorbed. A study performed by Walle <italic>et al.</italic><sup><xref ref-type="bibr" rid="bibr46-1535370212473704">46</xref></sup> using <sup>14</sup>C-<italic>trans</italic>-resveratrol (oral dose of 25 mg) in humans showed that 70% of the resveratrol dose was absorbed by the body. Metabolites of resveratrol (conjugated forms) in plasma peaked at 30–60 min postadministration with a plasma half-life of 9.2 h.<sup><xref ref-type="bibr" rid="bibr46-1535370212473704">46</xref></sup> In contrast, only small amounts of unmodified resveratrol (&lt;5 ng/mL) were detected in plasma in a similar timeframe. Resveratrol absorbed from the gastrointestinal tract is rapidly metabolized to glucuronide (3-<italic>O</italic>-glucuronide and 4′-<italic>O</italic>-glucuronide), sulfate (resveratrol 3-<italic>O</italic>-sulfate), and hydroxylate forms. The majority of orally dosed resveratrol is found in urine as sulfate- or glucuronic acid-conjugates. Food intake with a single dose of 400 mg <italic>trans</italic>-resveratrol delays absorption.<sup><xref ref-type="bibr" rid="bibr47-1535370212473704">47</xref></sup> Thus, orally ingested resveratrol is both rapidly metabolized and excreted, accounting for its low bioavailability. However, a few studies show that the bioavailability of resveratrol can be enhanced by using more potent resveratrol analogs (i.e. SRT501)<sup><xref ref-type="bibr" rid="bibr48-1535370212473704">48</xref></sup> and enhanced delivery methods such as liposomal encapsulation,<sup><xref ref-type="bibr" rid="bibr49-1535370212473704">49</xref></sup> or combining it with another natural product from black pepper (<italic>Piper spp</italic>.), piperine.<sup><xref ref-type="bibr" rid="bibr50-1535370212473704">50</xref></sup> However, further validation of these strategies will be needed before resveratrol can be used in diabetic pregnancy.</p>
</sec>
<sec id="sec5">
<title>Health benefits of resveratrol</title>
<p>According to ClinicalTrials.gov (<uri xlink:href="http://clinicaltrials.gov/">http://clinicaltrials.gov/</uri>), there are more than 50 recent studies involving resveratrol. These trials investigate the possible role of resveratrol in different diseases such as diabetes, Alzheimer's disease and cancer. There are 12 clinical trials where resveratrol is specifically being focused for type 2 diabetes, obesity, insulin resistance or metabolic syndrome.<sup><xref ref-type="bibr" rid="bibr51-1535370212473704">51</xref>,<xref ref-type="bibr" rid="bibr52-1535370212473704">52</xref></sup> One of the human clinical trial is investigating whether resveratrol when given orally to obese and type 2 diabetic subjects, will decrease reactive oxygen species (ROS) generation and prevent the production of the pro-inflammatory transcription factor nuclear factor-κB.<sup><xref ref-type="bibr" rid="bibr51-1535370212473704">51</xref></sup> A second trial is investigating the cellular and molecular effects of resveratrol on inflammatory mediators and insulin resistance in obese non-diabetic and type 2 diabetic subjects (<uri xlink:href="http://clinicaltrials.gov/">http://clinicaltrials.gov/</uri>). Another clinical trial is being conducted to determine the effect of resveratrol on endothelial function.<sup><xref ref-type="bibr" rid="bibr53-1535370212473704">53</xref></sup> The endothelium participates in the control of blood vessel function, in part by regulating vessel dilation via nitric oxide; however, endothelial function becomes abnormal in diabetic patients, and this abnormality contributes to the development of cardiovascular disease.<sup><xref ref-type="bibr" rid="bibr33-1535370212473704">33</xref></sup> In diabetic (Lepr<sup>db</sup>) mice, resveratrol restores endothelial function by interfering with tumor necrosis factor α-mediated activation of NADPH oxidase and thereby preserves nitric oxide availability.<sup><xref ref-type="bibr" rid="bibr54-1535370212473704">54</xref></sup> Preclinical observations suggest that resveratrol is safe and has enormous potential in the treatment of obesity and insulin resistance in humans. Current investigations are evaluating whether resveratrol is able to counteract the detrimental effects of obesity. One trial is examining the effect of resveratrol on improving the metabolic profile of adults with insulin resistance (<uri xlink:href="http://clinicaltrials.gov/">http://clinicaltrials.gov/</uri>). Resveratrol's antioxidative potential is being compared with calorie restriction in clinical trials to determine: (i) gene expression and lipid profile changes, (ii) insulin's efficacy to control blood sugar and (iii) changes in other blood and tissue markers of metabolic and cardiovascular health.<sup><xref ref-type="bibr" rid="bibr51-1535370212473704">51</xref></sup> Another current study with obese subjects is aimed to test resveratrol's ability to improve mitochondrial activity and fatty acid oxidative capacity in skeletal muscle upon a high-fat challenge (<uri xlink:href="http://clinicaltrials.gov/">http://clinicaltrials.gov/</uri>).</p>
</sec>
<sec id="sec6">
<title>Resveratrol improves maternal glucose and lipid profile during diabetic pregnancy</title>
<p>The ability of resveratrol to lower blood glucose is well documented.<sup><xref ref-type="bibr" rid="bibr42-1535370212473704">42</xref>,<xref ref-type="bibr" rid="bibr55-1535370212473704">55</xref></sup> In rodent studies, we tested this ability of resveratrol to lower blood glucose in pregnant diabetic dams where diabetes was induced with streptozotocin. Glucose concentrations were measured in dams on every other day of pregnancy and significant decreases at gestation day 9 (22.80%) and 12 (33.32%) were found in the resveratrol-treated diabetic group compared with the diabetic only group.<sup><xref ref-type="bibr" rid="bibr31-1535370212473704">31</xref></sup> In addition, significantly increased insulin levels were present in the resveratrol-fed diabetic groups, although it was still much lower than that in the control group.<sup><xref ref-type="bibr" rid="bibr31-1535370212473704">31</xref></sup> Diabetes also adversely affects lipid profile, which may indirectly affect embryogenesis and organogenesis.<sup><xref ref-type="bibr" rid="bibr56-1535370212473704">56</xref></sup> Furthermore, combined disruption of normal glucose and lipid status may be detrimental to fetal and neonatal growth; some evidence indicates that these effects may be lifelong and contribute to adult obesity. In our studies, excess lipids accumulate in the serum of diabetic dams; however, less lipid accumulation (comparable to that observed in controls) was found in the serum of rat diabetic dams treated with resveratrol.<sup><xref ref-type="bibr" rid="bibr31-1535370212473704">31</xref></sup> We further analyzed the lipid profile and found that resveratrol significantly decreased the cholesterol and triglycerides concentrations in the serum of diabetic dams.<sup><xref ref-type="bibr" rid="bibr31-1535370212473704">31</xref></sup> Recently, resveratrol was shown to reduce mRNA levels for HMG-CoA reductase (a rate-limiting enzyme for cholesterol synthesis and target for ‘statin’ drugs) in high-fat-diet-fed hamsters.<sup><xref ref-type="bibr" rid="bibr57-1535370212473704">57</xref></sup> Statin molecules are used as drugs to lower the cholesterol and triglycerides in humans, but are not recommended for pregnant or nursing mothers.<sup><xref ref-type="bibr" rid="bibr58-1535370212473704">58</xref>,<xref ref-type="bibr" rid="bibr59-1535370212473704">59</xref></sup> Therefore, resveratrol could be used as substitute for statins to control excess cholesterol production. Lipid profile is correlated with biologically active estrogen. So, the significant reduction in triglyceride level of diabetic female rat might be due to the ability of resveratrol to act on estrogen receptor signaling.<sup><xref ref-type="bibr" rid="bibr60-1535370212473704">60</xref>,<xref ref-type="bibr" rid="bibr61-1535370212473704">61</xref></sup> However, whether resveratrol activity is estrogenic or antiestrogenic remains controversial.<sup><xref ref-type="bibr" rid="bibr62-1535370212473704">62</xref>,<xref ref-type="bibr" rid="bibr63-1535370212473704">63</xref></sup></p>
</sec>
<sec id="sec7">
<title>Antiteratogenic effect of resveratrol</title>
<p>An antiteratogenic effect of resveratrol has been demonstrated in pregnant mice (C57BL/6J) exposed to 2,3,7,8-tetrachlorodibenzo-<italic>p</italic>-dioxin (TCDD). Pretreatment with resveratrol by gavage feeding (50 mg/kg body weight [bw]) from gestational day E8 to E13 significantly reduced the incidence and severity of fetal malformations caused by TCDD exposure (oral challenge, 14 <italic>μ</italic>g/kg bw on E12).<sup><xref ref-type="bibr" rid="bibr64-1535370212473704">64</xref></sup> In addition, resveratrol inhibited TCDD-induced immunotoxicity in both the mother and fetus. Resveratrol protects normal non-pregnant mice and pregnant dams and their fetuses from TCDD-induced thymic atrophy and apoptosis, from alterations in the expression of T-cell receptor and co-stimulatory molecules, and from alterations in T-cell differentiation.<sup><xref ref-type="bibr" rid="bibr65-1535370212473704">65</xref></sup> In another study, the effect of dietary resveratrol on embryo-fetal survival and development was evaluated in groups of pregnant female Sprague–Dawley rats. Treatment with resveratrol with up to 750 mg/kg bw per day (from gestation day 5 to 20) was well tolerated with no signs of adverse effects on fetal weights, number of implantations, resorptions, live young or pre and post implantation losses. Maternal treatment with resveratrol at dietary doses up to 750 mg/kg bw/day had no effect on the incidence of major or minor fetal abnormalities or the incidence of visceral abnormalities. It was concluded that up to 750 mg/kg bw per day of resveratrol dose represented the no-observed-adverse-effect-level for maternal toxicity and embryo-fetal development.<sup><xref ref-type="bibr" rid="bibr66-1535370212473704">66</xref></sup> Recently, in a human clinical trial healthy subjects tolerated a 4.0 g resveratrol dose; however, at this high dose, diarrhea was observed in some participants.<sup><xref ref-type="bibr" rid="bibr67-1535370212473704">67</xref></sup> In another study from our lab, we showed that resveratrol exhibits neuroprotective effects in cerebellum by acting at redox regulating proteins in a rodent model of fetal alcohol spectrum disorders.<sup><xref ref-type="bibr" rid="bibr68-1535370212473704">68</xref></sup></p>
</sec>
<sec id="sec8">
<title>Resveratrol prevents NTDs in diabetic pregnancies</title>
<p>Diabetic pregnancy can have many complications, especially in terms of embryonic development. Examples of embryonic impairments include improper or incomplete closure of the neural tube, developmental retardation, impaired rate of neurogenesis and failure to form appropriate neural connections.<sup><xref ref-type="bibr" rid="bibr4-1535370212473704">4</xref>,<xref ref-type="bibr" rid="bibr7-1535370212473704">7</xref></sup> Furthermore, these developmental issues may be the basis of many future physical, neurological and psychiatric disorders. In humans, diabetic malformations most likely occur during the first trimester.<sup><xref ref-type="bibr" rid="bibr69-1535370212473704">69</xref></sup> In embryos of diabetic rat dams, embryonic day 12 is the stage where organogenesis is affected.<sup><xref ref-type="bibr" rid="bibr70-1535370212473704">70</xref></sup> We evaluated the outcome of diabetic pregnancy in E12 embryos after gavage feeding of resveratrol (100 mg/kg bw) to diabetic dams. No external malformations were observed in the embryos of control or control treated with resveratrol group (Figure <xref ref-type="fig" rid="fig1-1535370212473704">1</xref>a). Approximately 20% of the embryos of diabetic dams were malformed (Figures <xref ref-type="fig" rid="fig1-1535370212473704">1</xref>b and c). The malformed embryos were characterized as having defect in neural tube closing. Collectively, these malformed embryos were categorized as having malformations.<sup><xref ref-type="bibr" rid="bibr71-1535370212473704">71</xref></sup> The number of malformed embryos was significantly reduced when diabetic dams received resveratrol treatment (Figure <xref ref-type="fig" rid="fig1-1535370212473704">1</xref>c). Most embryos of diabetic dams, including those that lacked obvious malformations, had reduced weight, crown-rump length and somite number,<sup><xref ref-type="bibr" rid="bibr31-1535370212473704">31</xref></sup> and reduced embryo size indicating developmental delay. Resveratrol not only abolishes the diabetes-induced malformation in the embryos but it also rescues embryos from developmental delays.<sup><xref ref-type="bibr" rid="bibr31-1535370212473704">31</xref></sup> One way that resveratrol might be acting directly on embryos of diabetic pregnancies is by normalizing hyperglycemia-induced oxidative stress. Apoptosis subsequent to oxidative stress is associated with diabetic embryopathies.<sup><xref ref-type="bibr" rid="bibr12-1535370212473704">12</xref></sup> In embryos, resveratrol normalizes oxidative stress markers including the increased lipid peroxidation and total thiol concentrations and decreased amounts of reduced glutathione associated with hyperglycemia.<sup><xref ref-type="bibr" rid="bibr31-1535370212473704">31</xref></sup> Attenuation of oxidative stress further reduces the level of activated caspases, thereby reducing apoptosis, and in turn reduces embryonic malformations.<sup><xref ref-type="bibr" rid="bibr31-1535370212473704">31</xref></sup>
<fig id="fig1-1535370212473704"><label>Figure 1</label>
<caption><p>Resveratrol prevents neural tube defects in E12 rat embryos of diabetic dams. (a) Morphological analysis of E12 rat embryos of control (C), control treated with resveratrol (CR), diabetic (D) and diabetic treated with resveratrol (DR) dams; (b) E12 rat embryos of diabetic dams with neural tube defects; (c) Percentage of malformed embryos in C, CR, D and DR groups</p></caption>
<graphic xlink:href="10.1177_1535370212473704-fig1.tif"/>
</fig></p>
</sec>
<sec id="sec9">
<title>Molecular mechanisms underlying the beneficial effects of resveratrol in diabetic embryopathy</title>
<p>Resveratrol crosses the blood–brain barrier and exerts protective effects against cerebral ischemic injury<sup><xref ref-type="bibr" rid="bibr72-1535370212473704">72</xref></sup> and also exerts potent antioxidant features in the brain of healthy rats.<sup><xref ref-type="bibr" rid="bibr73-1535370212473704">73</xref></sup> There have been no reports, however, on whether resveratrol crosses the placental barrier. Because resveratrol is beneficial against diabetes-induced embryonic malformation, we might cautiously assume that it does cross the placental barrier. Resveratrol works positively in different ways on mother and embryo in diabetic pregnancy to normalize the disease condition.<sup><xref ref-type="bibr" rid="bibr31-1535370212473704">31</xref></sup> Improvement in embryonic outcome might be because of improved maternal environment, direct effects on the embryos (as evident from normalized embryonic oxidative stress level), or both.<sup><xref ref-type="bibr" rid="bibr31-1535370212473704">31</xref></sup> Diabetes-dependent increases in oxidative stress and its fluctuation, and individual fetal antioxidative capacity determine the severity of embryonic deformity. Diabetic embryopathy studies revealed that the outcome of embryonic development depends on the glycemic, cholesterol and triglyceride levels and on the level of oxidative stress.<sup><xref ref-type="bibr" rid="bibr12-1535370212473704">12</xref>,<xref ref-type="bibr" rid="bibr31-1535370212473704">31</xref></sup></p>
<p>We found that administration of resveratrol, a potent antioxidant<sup><xref ref-type="bibr" rid="bibr74-1535370212473704">74</xref></sup> in diabetic pregnancy works via three different ways by: (i) reducing excess maternal cholesterol and triglyceride, (ii) reducing maternal blood sugar level and (iii) modulating embryonic oxidative stress and apoptosis.<sup><xref ref-type="bibr" rid="bibr31-1535370212473704">31</xref></sup> Resveratrol is a free radical-scavenger and a potent antioxidant and can promote the activities of several antioxidative enzymes.<sup><xref ref-type="bibr" rid="bibr75-1535370212473704">75</xref></sup> Reactive oxygen species (ROS) are important intermediates in cellular signal transduction and transcriptional control but excess ROS generation leads to harmful oxidative modification of cellular lipids, proteins and nucleic acids. Indeed, diabetes-induced complications are associated with the increased amounts of ROS. In diabetic dams, with resveratrol treatment there were no changes in expression or activity of the antioxidative enzyme superoxide dismutase, but resveratrol reduced oxidative stress by normalizing the level of reduced glutathione, total thiol, lipid peroxidation and 4-hydroxy-2-non-enal (HNE) accumulation. Excess level of oxidative stress induces the formation of electrophilic aldehydes, such as HNE, as by-products of peroxidation of lipid membranes.<sup><xref ref-type="bibr" rid="bibr76-1535370212473704">76</xref></sup> HNE exerts its effects by alterations in cell proliferation, cell-cycle progression and apoptosis in various cell types.<sup><xref ref-type="bibr" rid="bibr76-1535370212473704">76</xref>,<xref ref-type="bibr" rid="bibr77-1535370212473704">77</xref></sup></p>
</sec>
<sec id="sec10">
<title>Diabetes impairs Rho GTPase signaling. Could resveratrol reverse impairments?</title>
<p>Rho GTPases (RhoA and Rac1), small-molecular weight G proteins of the Ras superfamily, have been implicated in cellular processes such as cytoskeletal rearrangement and cell-cycle control.<sup><xref ref-type="bibr" rid="bibr78-1535370212473704">78</xref>–<xref ref-type="bibr" rid="bibr82-1535370212473704">82</xref></sup> Active (GTP-bound) and inactive (GDP-bound) Rho conformations function as controls in a myriad of intracellular processes. Conformational cycling is regulated by three main classes of proteins: (i) those catalyzing exchange of GDP for GTP (e.g. guanosine nucleotide exchange factors);<sup><xref ref-type="bibr" rid="bibr83-1535370212473704">83</xref></sup> (ii) those stimulating hydrolysis of GTP to GDP (e.g. GTPase activating proteins [GAPs]);<sup><xref ref-type="bibr" rid="bibr84-1535370212473704">84</xref></sup> and (iii) those inhibiting the dissociation of GDP from GTPase (e.g. GDP dissociation inhibitors [GDIs]).<sup><xref ref-type="bibr" rid="bibr85-1535370212473704">85</xref></sup> Rho GTPases are also involved in neural tube closing<sup><xref ref-type="bibr" rid="bibr86-1535370212473704">86</xref>–<xref ref-type="bibr" rid="bibr89-1535370212473704">89</xref></sup> whereby RhoA accumulates at the apical region of neural plate to promote folding.<sup><xref ref-type="bibr" rid="bibr87-1535370212473704">87</xref>,<xref ref-type="bibr" rid="bibr90-1535370212473704">90</xref></sup> Enrichment of RhoA at the apical region of the plate induces the constriction of the cells via Rho kinase. The resulting cytoskeletal rearrangement promotes the bending of the plate.<sup><xref ref-type="bibr" rid="bibr90-1535370212473704">90</xref></sup> G protein-coupled receptors such as Par1 and Par2 participate in neural tube closing. Genetic deletion of Par1/Par2 yields NTDs.<sup><xref ref-type="bibr" rid="bibr91-1535370212473704">91</xref></sup> These receptors function by coupling to heterotrimeric G proteins such as Go, Gi and Gz. Pertussis toxin, which inactivates these G proteins, reproduces the NTD-forming effects of Par1 and Par2 genetic. More importantly, Rac1 genetic deletion also produces exencephaly and spina bifida in mouse embryos.<sup><xref ref-type="bibr" rid="bibr91-1535370212473704">91</xref></sup></p>
<p>Rho GTPases play key roles in cytoskeletal re-arrangement and neuronal differentiation. During normal development, activation of RhoA leads to formation of stress fibers and focal adhesion complexes.<sup><xref ref-type="bibr" rid="bibr79-1535370212473704">79</xref></sup> On the other hand, Rac1 activation participates in membrane ruffling and lamellipodia formation.<sup><xref ref-type="bibr" rid="bibr81-1535370212473704">81</xref></sup> Studies conducted in primary neurons suggest that Rho GTPases help to regulate the growth of axons and other neuronal processes. In general, Rac1 has a positive effect on neurite extension, whereas RhoA has a positive effect on neurite retraction.<sup><xref ref-type="bibr" rid="bibr92-1535370212473704">92</xref>–<xref ref-type="bibr" rid="bibr94-1535370212473704">94</xref></sup> Experimental evidence indicates that formation of synaptic connections in the neuronal network and their rearrangement are governed by the neuronal actin cytoskeleton.<sup><xref ref-type="bibr" rid="bibr95-1535370212473704">95</xref>,<xref ref-type="bibr" rid="bibr96-1535370212473704">96</xref></sup> Actin assembly and polymerization as well as actomycin contraction are chiefly regulated by Rho GTPases.<sup><xref ref-type="bibr" rid="bibr97-1535370212473704">97</xref>,<xref ref-type="bibr" rid="bibr98-1535370212473704">98</xref></sup> Thus, by controlling neuronal morphology, Rho GTPases might also be essential for learning and memory. Indeed, activation of Rho GTPases by CNF1 toxin induces cerebral actin cytoskeletal re-arrangement and improves learning and memory, as judged by various behavioral tests.<sup><xref ref-type="bibr" rid="bibr99-1535370212473704">99</xref></sup> Although many aspects of Rho signaling in the central nervous system are still unclear, the emerging details reveal that alterations or impairments in Rho GTPase signaling result in abnormal neuronal connectivity and deficient cognitive functioning in humans.<sup><xref ref-type="bibr" rid="bibr100-1535370212473704">100</xref></sup> Rho GTPases participate in retinoic acid (RA)-induced neuronal differentiation. Whereas activation of RhoA is involved in cytoskeletal rearrangement, Rac1 regulates induction of neurite outgrowth.<sup><xref ref-type="bibr" rid="bibr80-1535370212473704">80</xref>,<xref ref-type="bibr" rid="bibr82-1535370212473704">82</xref></sup> After activation, Rho GTPases bind to their kinase effectors (ROCK-2 for RhoA and PAK1 for Rac1) and translocate to the plasma membrane.<sup><xref ref-type="bibr" rid="bibr79-1535370212473704">79</xref>,<xref ref-type="bibr" rid="bibr101-1535370212473704">101</xref></sup> Oxidative stress activates RhoA; the ROS produced during oxidative stress react with the redox-sensitive cysteine residues in the phosphoryl-binding loop of RhoA, promoting its activation. This activation does not require the participation of exchange factors or other regulating proteins.<sup><xref ref-type="bibr" rid="bibr102-1535370212473704">102</xref></sup> In another study, ROS promoted the activation of RhoA by dissociating Rho GDI. The removal of ROS by the scavenger Tiron prevented the activation of RhoA <italic>in vivo.</italic><sup><xref ref-type="bibr" rid="bibr103-1535370212473704">103</xref></sup> Whether hyperglycemia also activates RhoA by increasing oxidative stress and whether resveratrol prevents oxidative stress to neutralize activation of RhoA are not known.</p>
<p>Diabetes-induced impairments in the activation of Rho GTPase signaling may contribute to neuronal malformations in diabetic embryopathy. Resveratrol corrects the diabetes-induced impairment of retinoic acid receptor (RAR), retinoid X receptor (RXR) and mitogen-activated protein kinase (MAPKs) expression. All these signals play crucial roles during embryonic development. In addition, RARs (RARα/β/γ) and RXRs (RXRα/β/γ) function as transcription factors controlling RA-directed gene expression.<sup><xref ref-type="bibr" rid="bibr104-1535370212473704">104</xref></sup> RA (a physiological active metabolite of vitamin A) is necessary for proper embryonic development and rostrocaudal patterning of the nervous system.<sup><xref ref-type="bibr" rid="bibr105-1535370212473704">105</xref></sup> As heterodimers, RARs and RXRs bind to RA-response elements in DNA of promoters of target genes to regulate their transcription.<sup><xref ref-type="bibr" rid="bibr104-1535370212473704">104</xref></sup> Vitamin A deficiency results in suppression of RAR activity and contributes to embryonic skeleton hypoplasia.<sup><xref ref-type="bibr" rid="bibr106-1535370212473704">106</xref></sup> The curly tail-mouse mutant (a model for NTD) displays NTD because of downregulated RARβ and RARγ expression.<sup><xref ref-type="bibr" rid="bibr107-1535370212473704">107</xref></sup> Activation of RARs and RXRs has an anti-diabetic effect and helps to activate insulin-sensitizing genes.<sup><xref ref-type="bibr" rid="bibr108-1535370212473704">108</xref></sup> Suppressed expression of RAR and RXR receptors in E12 embryo of diabetic dams was improved with resveratrol treatment.<sup><xref ref-type="bibr" rid="bibr109-1535370212473704">109</xref></sup> MAPKs also contribute to growth, differentiation and developmental processes; their activity determines the fate of embryonic organogenesis when the embryo faces teratogenic conditions.<sup><xref ref-type="bibr" rid="bibr110-1535370212473704">110</xref></sup> Hyperglycemia increases ROS, which modulate MAPK signaling.<sup><xref ref-type="bibr" rid="bibr111-1535370212473704">111</xref></sup> In the embryo, oxidative stress results in DNA, protein and lipid modifications that disrupt normal development. Resveratrol can also selectively inhibit stress activated MAPK signaling.<sup><xref ref-type="bibr" rid="bibr112-1535370212473704">112</xref></sup> Increased phospho-ERK1/2 and decreased phospho-JNK1/2 and phospho-p38 occurs in the embryos of resveratrol-treated diabetic dams compared with those not exposed to resveratrol.<sup><xref ref-type="bibr" rid="bibr109-1535370212473704">109</xref></sup></p>
<p>After reviewing the literature on resveratrol, and on the basis of our own studies, we conclude that resveratrol possesses significant blood sugar-lowering activity and antioxidative capacity without any observable side-effects<sup><xref ref-type="bibr" rid="bibr31-1535370212473704">31</xref>,<xref ref-type="bibr" rid="bibr45-1535370212473704">45</xref></sup> and prevents embryonic oxidative stress and apoptosis associated with diabetic embryopathy. Thus, resveratrol may be suitable alone or in combination with insulin and folic acid for use during diabetic pregnancies and for nursing mothers. Animal studies to test whether resveratrol supplementation in combination with folic acid alone and/or with insulin can prevent all embryonic malformations and developmental delays are needed to provide data to support clinical trials in humans.</p>
<p><bold>Author contributions</bold>: CKS and USS designed the study; CKS conducted the study; AK contributed to the study design; CKS, HAL and USS wrote the manuscript; CKS, DD and USS were involved in the data analyses and interpretation and review of the manuscript.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>This research was supported in part by NIH R21AA016121 (US) and Health Sciences Distinguished Professorship (DJD).</p>
</ack>
<ref-list><title>References</title>
<ref id="bibr1-1535370212473704"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Polonsky</surname><given-names>KS</given-names></name></person-group>. <article-title>The past 200 years in diabetes</article-title>. <source>N Eng J Med</source> <year>2012</year>;<volume>367</volume>:<fpage>1332</fpage>–<lpage>40</lpage></citation></ref>
<ref id="bibr2-1535370212473704"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Evensen</surname><given-names>AE</given-names></name></person-group>. <article-title>Update on gestational diabetes mellitus</article-title>. <source>Prim Care</source> <year>2012</year>;<volume>39</volume>:<fpage>83</fpage>–<lpage>94</lpage></citation></ref>
<ref id="bibr3-1535370212473704"><label>3</label><citation citation-type="book"><collab>Centers for Disease Control and Prevention</collab>. <source>National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011</source>. <publisher-loc>Atlanta, GA</publisher-loc>: <publisher-name>US Department of Health and Human Services, Centers for Disease Control and Prevention</publisher-name>, <year>2011</year></citation></ref>
<ref id="bibr4-1535370212473704"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Becerra</surname><given-names>JE</given-names></name><name><surname>Khoury</surname><given-names>MJ</given-names></name><name><surname>Cordero</surname><given-names>JF</given-names></name><name><surname>Erickson</surname><given-names>JD</given-names></name></person-group>. <article-title>Diabetes mellitus during pregnancy and the risks for specific birth defects: a population-based case-control study</article-title>. <source>Pediatrics</source> <year>1990</year>;<volume>85</volume>:<fpage>1</fpage>–<lpage>9</lpage></citation></ref>
<ref id="bibr5-1535370212473704"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>JL</given-names></name></person-group>. <article-title>Malformations in infants of diabetic mothers</article-title>. <source>Teratology</source> <year>1982</year>;<volume>25</volume>:<fpage>385</fpage>–<lpage>94</lpage></citation></ref>
<ref id="bibr6-1535370212473704"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Phelan</surname><given-names>SA</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Loeken</surname><given-names>MR</given-names></name></person-group>. <article-title>Neural tube defects in embryos of diabetic mice: role of the Pax-3 gene and apoptosis</article-title>. <source>Diabetes</source> <year>1997</year>;<volume>46</volume>:<fpage>1189</fpage>–<lpage>97</lpage></citation></ref>
<ref id="bibr7-1535370212473704"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cederberg</surname><given-names>J</given-names></name><name><surname>Picard</surname><given-names>JJ</given-names></name><name><surname>Eriksson</surname><given-names>UJ</given-names></name></person-group>. <article-title>Maternal diabetes in the rat impairs the formation of neural-crest derived cranial nerve ganglia in the offspring</article-title>. <source>Diabetologia</source> <year>2003</year>;<volume>46</volume>:<fpage>1245</fpage>–<lpage>51</lpage></citation></ref>
<ref id="bibr8-1535370212473704"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>LM</given-names></name><name><surname>Tygstrup</surname><given-names>I</given-names></name><name><surname>Pedersen</surname><given-names>J</given-names></name></person-group>. <article-title>Congenital malformations in newborn Infants of diabetic women. Correlation with maternal diabetic vascular complications</article-title>. <source>Lancet</source> <year>1964</year>;<volume>1</volume>:<fpage>1124</fpage>–<lpage>26</lpage></citation></ref>
<ref id="bibr9-1535370212473704"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Reece</surname><given-names>EA</given-names></name></person-group>. <article-title>Experimental mechanisms of diabetic embryopathy and strategies for developing therapeutic interventions</article-title>. <source>J Soc Gynecol Investig</source> <year>2005</year>;<volume>12</volume>:<fpage>549</fpage>–<lpage>57</lpage></citation></ref>
<ref id="bibr10-1535370212473704"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eriksson</surname><given-names>UJ</given-names></name><name><surname>Cederberg</surname><given-names>J</given-names></name><name><surname>Wentzel</surname><given-names>P</given-names></name></person-group>. <article-title>Congenital malformations in offspring of diabetic mothers – animal and human studies</article-title>. <source>Rev Endocr Metab Disord</source> <year>2003</year>;<volume>4</volume>:<fpage>79</fpage>–<lpage>93</lpage></citation></ref>
<ref id="bibr11-1535370212473704"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salbaum</surname><given-names>JM</given-names></name><name><surname>Kappen</surname><given-names>C</given-names></name></person-group>. <article-title>Neural tube defect genes and maternal diabetes during pregnancy</article-title>. <source>Birth Defects Res A Clin Mol Teratol</source> <year>2010</year>;<volume>88</volume>:<fpage>601</fpage>–<lpage>11</lpage></citation></ref>
<ref id="bibr12-1535370212473704"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ornoy</surname><given-names>A</given-names></name></person-group>. <article-title>Embryonic oxidative stress as a mechanism of teratogenesis with special emphasis on diabetic embryopathy</article-title>. <source>Reprod Toxicol</source> <year>2007</year>;<volume>24</volume>:<fpage>31</fpage>–<lpage>41</lpage></citation></ref>
<ref id="bibr13-1535370212473704"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zabihi</surname><given-names>S</given-names></name><name><surname>Wentzel</surname><given-names>P</given-names></name><name><surname>Eriksson</surname><given-names>UJ</given-names></name></person-group>. <article-title>Maternal blood glucose levels determine the severity of diabetic embryopathy in mice with different expression of copper-zinc superoxide dismutase (CuZnSOD)</article-title>. <source>Toxicol Sci</source> <year>2008</year>;<volume>105</volume>:<fpage>166</fpage>–<lpage>72</lpage></citation></ref>
<ref id="bibr14-1535370212473704"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Reece</surname><given-names>EA</given-names></name></person-group>. <article-title>Involvement of c-Jun N-terminal kinases activation in diabetic embryopathy</article-title>. <source>Biochem Biophys Res Commun</source> <year>2007</year>;<volume>357</volume>:<fpage>749</fpage>–<lpage>54</lpage></citation></ref>
<ref id="bibr15-1535370212473704"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Soler</surname><given-names>NG</given-names></name><name><surname>Walsh</surname><given-names>CH</given-names></name><name><surname>Malins</surname><given-names>JM</given-names></name></person-group>. <article-title>Congenital malformations in infants of diabetic mothers</article-title>. <source>Q J Med</source> <year>1976</year>;<volume>45</volume>:<fpage>303</fpage>–<lpage>13</lpage></citation></ref>
<ref id="bibr16-1535370212473704"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zabihi</surname><given-names>S</given-names></name><name><surname>Loeken</surname><given-names>MR</given-names></name></person-group>. <article-title>Understanding diabetic teratogenesis: where are we now and where are we going?</article-title> <source>Birth Defects Res A Clin Mol Teratol</source> <year>2010</year>;<volume>88</volume>:<fpage>779</fpage>–<lpage>90</lpage></citation></ref>
<ref id="bibr17-1535370212473704"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Evers</surname><given-names>IM</given-names></name><name><surname>de Valk</surname><given-names>HW</given-names></name><name><surname>Visser</surname><given-names>GH</given-names></name></person-group>. <article-title>Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands</article-title>. <source>Br Med J</source> <year>2004</year>;<volume>328</volume>:<fpage>915</fpage></citation></ref>
<ref id="bibr18-1535370212473704"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suhonen</surname><given-names>L</given-names></name><name><surname>Hiilesmaa</surname><given-names>V</given-names></name><name><surname>Teramo</surname><given-names>K</given-names></name></person-group>. <article-title>Glycaemic control during early pregnancy and fetal malformations in women with type I diabetes mellitus</article-title>. <source>Diabetologia</source> <year>2000</year>;<volume>43</volume>:<fpage>79</fpage>–<lpage>82</lpage></citation></ref>
<ref id="bibr19-1535370212473704"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Loeken</surname><given-names>MR</given-names></name></person-group>. <article-title>Challenges in understanding diabetic embryopathy</article-title>. <source>Diabetes</source> <year>2008</year>;<volume>57</volume>:<fpage>3187</fpage>–<lpage>8</lpage></citation></ref>
<ref id="bibr20-1535370212473704"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>JL</given-names></name><name><surname>Signore</surname><given-names>CC</given-names></name></person-group>. <article-title>Folic acid and the prevention of neural-tube defects</article-title>. <source>N Engl J Med</source> <year>2004</year>;<volume>350</volume>:<fpage>2209</fpage>–<lpage>11</lpage></citation></ref>
<ref id="bibr21-1535370212473704"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gareskog</surname><given-names>M</given-names></name><name><surname>Eriksson</surname><given-names>UJ</given-names></name><name><surname>Wentzel</surname><given-names>P</given-names></name></person-group>. <article-title>Combined supplementation of folic acid and vitamin E diminishes diabetes-induced embryotoxicity in rats</article-title>. <source>Birth Defects Res A Clin Mol Teratol</source> <year>2006</year>;<volume>76</volume>:<fpage>483</fpage>–<lpage>90</lpage></citation></ref>
<ref id="bibr22-1535370212473704"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wentzel</surname><given-names>P</given-names></name><name><surname>Gareskog</surname><given-names>M</given-names></name><name><surname>Eriksson</surname><given-names>UJ</given-names></name></person-group>. <article-title>Folic acid supplementation diminishes diabetes- and glucose-induced dysmorphogenesis in rat embryos in vivo and in vitro</article-title>. <source>Diabetes</source> <year>2005</year>;<volume>54</volume>:<fpage>546</fpage>–<lpage>53</lpage></citation></ref>
<ref id="bibr23-1535370212473704"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>JL</given-names></name><name><surname>Signore</surname><given-names>C</given-names></name></person-group>. <article-title>Neural tube defect rates before and after food fortification with folic acid</article-title>. <source>Birth Defects Res A Clin Mol Teratol</source> <year>2004</year>;<volume>70</volume>:<fpage>844</fpage>–<lpage>45</lpage></citation></ref>
<ref id="bibr24-1535370212473704"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wolff</surname><given-names>T</given-names></name><name><surname>Witkop</surname><given-names>CT</given-names></name><name><surname>Miller</surname><given-names>T</given-names></name><name><surname>Syed</surname><given-names>SB</given-names></name></person-group>. <article-title>Folic acid supplementation for the prevention of neural tube defects: an update of the evidence for the US Preventive Services Task Force</article-title>. <source>Ann Intern Med</source> <year>2009</year>;<volume>150</volume>:<fpage>632</fpage>–<lpage>39</lpage></citation></ref>
<ref id="bibr25-1535370212473704"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Banhidy</surname><given-names>F</given-names></name><name><surname>Acs</surname><given-names>N</given-names></name><name><surname>Puho</surname><given-names>EH</given-names></name><name><surname>Czeizel</surname><given-names>AE</given-names></name></person-group>. <article-title>Congenital abnormalities in the offspring of pregnant women with type 1, type 2 and gestational diabetes mellitus: a population-based case-control study</article-title>. <source>Congenit Anom (Kyoto)</source> <year>2010</year>;<volume>50</volume>:<fpage>115</fpage>–<lpage>21</lpage></citation></ref>
<ref id="bibr26-1535370212473704"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>RD</given-names></name><name><surname>Davies</surname><given-names>G</given-names></name><name><surname>Desilets</surname><given-names>V</given-names></name><name><surname>Reid</surname><given-names>GJ</given-names></name><name><surname>Summers</surname><given-names>A</given-names></name><name><surname>Wyatt</surname><given-names>P</given-names></name><name><surname>Young</surname><given-names>D</given-names></name></person-group>. <article-title>The use of folic acid for the prevention of neural tube defects and other congenital anomalies</article-title>. <source>J Obstet Gynaecol Can</source> <year>2003</year>;<volume>25</volume>:<fpage>959</fpage>–<lpage>73</lpage></citation></ref>
<ref id="bibr27-1535370212473704"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>KC</given-names></name><name><surname>Friso</surname><given-names>S</given-names></name><name><surname>Choi</surname><given-names>SW</given-names></name></person-group>. <article-title>DNA methylation, an epigenetic mechanism connecting folate to healthy embryonic development and aging</article-title>. <source>J Nutr Biochem</source> <year>2009</year>;<volume>20</volume>:<fpage>917</fpage>–<lpage>26</lpage></citation></ref>
<ref id="bibr28-1535370212473704"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>EJ</given-names></name></person-group>. <article-title>Has enhanced folate status during pregnancy altered natural selection and possibly Autism prevalence? A closer look at a possible link</article-title>. <source>Med Hypotheses</source> <year>2008</year>;<volume>71</volume>:<fpage>406</fpage>–<lpage>10</lpage></citation></ref>
<ref id="bibr29-1535370212473704"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Callejon</surname><given-names>G</given-names></name><name><surname>Mayor-Olea</surname><given-names>A</given-names></name><name><surname>Jimenez</surname><given-names>AJ</given-names></name><name><surname>Gaitan</surname><given-names>MJ</given-names></name><name><surname>Palomares</surname><given-names>AR</given-names></name><name><surname>Martinez</surname><given-names>F</given-names></name><name><surname>Ruiz</surname><given-names>M</given-names></name><name><surname>Reyes-Engel</surname><given-names>A</given-names></name></person-group>. <article-title>Genotypes of the C677T and A1298C polymorphisms of the MTHFR gene as a cause of human spontaneous embryo loss</article-title>. <source>Hum Reprod</source> <year>2007</year>;<volume>22</volume>:<fpage>3249</fpage>–<lpage>54</lpage></citation></ref>
<ref id="bibr30-1535370212473704"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Do</surname><given-names>GM</given-names></name><name><surname>Jung</surname><given-names>UJ</given-names></name><name><surname>Park</surname><given-names>HJ</given-names></name><name><surname>Kwon</surname><given-names>EY</given-names></name><name><surname>Jeon</surname><given-names>SM</given-names></name><name><surname>McGregor</surname><given-names>RA</given-names></name><name><surname>Choi</surname><given-names>MS</given-names></name></person-group>. <article-title>Resveratrol ameliorates diabetes-related metabolic changes via activation of AMP-activated protein kinase and its downstream targets in db/db mice</article-title>. <source>Mol Nutr Food Res</source> <year>2012</year>;<volume>56</volume>:<fpage>1282</fpage>–<lpage>91</lpage></citation></ref>
<ref id="bibr31-1535370212473704"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>CK</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Hitchcock</surname><given-names>DB</given-names></name><name><surname>Fan</surname><given-names>D</given-names></name><name><surname>Goodwin</surname><given-names>R</given-names></name><name><surname>Lavoie</surname><given-names>HA</given-names></name><name><surname>Nagarkatti</surname><given-names>P</given-names></name><name><surname>Dipette</surname><given-names>DJ</given-names></name><name><surname>Singh</surname><given-names>US</given-names></name></person-group>. <article-title>Resveratrol prevents embryonic oxidative stress and apoptosis associated with diabetic embryopathy and improves glucose and lipid profile of diabetic dam</article-title>. <source>Mol Nutr Food Res</source> <year>2011</year>;<volume>55</volume>:<fpage>1186</fpage>–<lpage>96</lpage></citation></ref>
<ref id="bibr32-1535370212473704"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>Y</given-names></name></person-group>. <article-title>Large-scale separation of resveratrol, anthraglycoside A and anthraglycoside B from Polygonum cuspidatum Sieb. et Zucc by high-speed counter-current chromatography</article-title>. <source>J Chromatogr A</source> <year>2001</year>;<volume>919</volume>:<fpage>443</fpage>–<lpage>48</lpage></citation></ref>
<ref id="bibr33-1535370212473704"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Magyar</surname><given-names>K</given-names></name><name><surname>Halmosi</surname><given-names>R</given-names></name><name><surname>Palfi</surname><given-names>A</given-names></name><name><surname>Feher</surname><given-names>G</given-names></name><name><surname>Czopf</surname><given-names>L</given-names></name><name><surname>Fulop</surname><given-names>A</given-names></name><name><surname>Battyany</surname><given-names>I</given-names></name><name><surname>Sumegi</surname><given-names>B</given-names></name><name><surname>Toth</surname><given-names>K</given-names></name><name><surname>Szabados</surname><given-names>E</given-names></name></person-group>. <article-title>Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease</article-title>. <source>Clin Hemorheol Microcirc</source> <year>2012</year>;<volume>50</volume>:<fpage>179</fpage>–<lpage>87</lpage></citation></ref>
<ref id="bibr34-1535370212473704"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bishayee</surname><given-names>A</given-names></name><name><surname>Politis</surname><given-names>T</given-names></name><name><surname>Darvesh</surname><given-names>AS</given-names></name></person-group>. <article-title>Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma</article-title>. <source>Cancer Treat Rev</source> <year>2010</year>;<volume>36</volume>:<fpage>43</fpage>–<lpage>53</lpage></citation></ref>
<ref id="bibr35-1535370212473704"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fulda</surname><given-names>S</given-names></name></person-group>. <article-title>Resveratrol and derivatives for the prevention and treatment of cancer</article-title>. <source>Drug Discov Today</source> <year>2010</year>;<volume>15</volume>:<fpage>757</fpage>–<lpage>65</lpage></citation></ref>
<ref id="bibr36-1535370212473704"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Howitz</surname><given-names>KT</given-names></name><name><surname>Bitterman</surname><given-names>KJ</given-names></name><name><surname>Cohen</surname><given-names>HY</given-names></name><name><surname>Lamming</surname><given-names>DW</given-names></name><name><surname>Lavu</surname><given-names>S</given-names></name><name><surname>Wood</surname><given-names>JG</given-names></name><name><surname>Zipkin</surname><given-names>RE</given-names></name><name><surname>Chung</surname><given-names>P</given-names></name><name><surname>Kisielewski</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>LL</given-names></name><name><surname>Scherer</surname><given-names>B</given-names></name><name><surname>Sinclair</surname><given-names>DA</given-names></name></person-group>. <article-title>Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan</article-title>. <source>Nature</source> <year>2003</year>;<volume>425</volume>:<fpage>191</fpage>–<lpage>96</lpage></citation></ref>
<ref id="bibr37-1535370212473704"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Valenzano</surname><given-names>DR</given-names></name><name><surname>Cellerino</surname><given-names>A</given-names></name></person-group>. <article-title>Resveratrol and the pharmacology of aging: a new vertebrate model to validate an old molecule</article-title>. <source>Cell Cycle</source> <year>2006</year>;<volume>5</volume>:<fpage>1027</fpage>–<lpage>32</lpage></citation></ref>
<ref id="bibr38-1535370212473704"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>B</given-names></name><name><surname>Masih</surname><given-names>I</given-names></name><name><surname>Deopujari</surname><given-names>J</given-names></name><name><surname>Charpentier</surname><given-names>C</given-names></name></person-group>. <article-title>Occurrence of resveratrol and pterostilbene in age-old darakchasava, an ayurvedic medicine from India</article-title>. <source>J Ethnopharmacol</source> <year>1999</year>;<volume>68</volume>:<fpage>71</fpage>–<lpage>76</lpage></citation></ref>
<ref id="bibr39-1535370212473704"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramadori</surname><given-names>G</given-names></name><name><surname>Gautron</surname><given-names>L</given-names></name><name><surname>Fujikawa</surname><given-names>T</given-names></name><name><surname>Vianna</surname><given-names>CR</given-names></name><name><surname>Elmquist</surname><given-names>JK</given-names></name><name><surname>Coppari</surname><given-names>R</given-names></name></person-group>. <article-title>Central administration of resveratrol improves diet-induced diabetes</article-title>. <source>Endocrinology</source> <year>2009</year>;<volume>150</volume>:<fpage>5326</fpage>–<lpage>33</lpage></citation></ref>
<ref id="bibr40-1535370212473704"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Milne</surname><given-names>JC</given-names></name><name><surname>Lambert</surname><given-names>PD</given-names></name><name><surname>Schenk</surname><given-names>S</given-names></name><name><surname>Carney</surname><given-names>DP</given-names></name><name><surname>Smith</surname><given-names>JJ</given-names></name><name><surname>Gagne</surname><given-names>DJ</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Boss</surname><given-names>O</given-names></name><name><surname>Perni</surname><given-names>RB</given-names></name><name><surname>Vu</surname><given-names>CB</given-names></name><name><surname>Bemis</surname><given-names>JE</given-names></name><name><surname>Xie</surname><given-names>R</given-names></name><name><surname>Disch</surname><given-names>JS</given-names></name><name><surname>Ng</surname><given-names>PY</given-names></name><name><surname>Nunes</surname><given-names>JJ</given-names></name><name><surname>Lynch</surname><given-names>AV</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Galonek</surname><given-names>H</given-names></name><name><surname>Israelian</surname><given-names>K</given-names></name><name><surname>Choy</surname><given-names>W</given-names></name><name><surname>Iffland</surname><given-names>A</given-names></name><name><surname>Lavu</surname><given-names>S</given-names></name><name><surname>Medvedik</surname><given-names>O</given-names></name><name><surname>Sinclair</surname><given-names>DA</given-names></name><name><surname>Olefsky</surname><given-names>JM</given-names></name><name><surname>Jirousek</surname><given-names>MR</given-names></name><name><surname>Elliott</surname><given-names>PJ</given-names></name><name><surname>Westphal</surname><given-names>CH</given-names></name></person-group>. <article-title>Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes</article-title>. <source>Nature</source> <year>2007</year>;<volume>450</volume>:<fpage>712</fpage>–<lpage>16</lpage></citation></ref>
<ref id="bibr41-1535370212473704"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Misra</surname><given-names>CS</given-names></name><name><surname>Arumugam</surname><given-names>S</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name><name><surname>Shah</surname><given-names>V</given-names></name><name><surname>Davis</surname><given-names>JA</given-names></name><name><surname>Shirumalla</surname><given-names>RK</given-names></name><name><surname>Ray</surname><given-names>A</given-names></name></person-group>. <article-title>Antidiabetic activity of resveratrol, a known SIRT1 activator in a genetic model for type-2 diabetes</article-title>. <source>Phytother Res</source> <year>2011</year>;<volume>25</volume>:<fpage>67</fpage>–<lpage>73</lpage></citation></ref>
<ref id="bibr42-1535370212473704"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Palsamy</surname><given-names>P</given-names></name><name><surname>Subramanian</surname><given-names>S</given-names></name></person-group>. <article-title>Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats</article-title>. <source>Biomed Pharmacother</source> <year>2008</year>;<volume>62</volume>:<fpage>598</fpage>–<lpage>605</lpage></citation></ref>
<ref id="bibr43-1535370212473704"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baur</surname><given-names>JA</given-names></name><name><surname>Pearson</surname><given-names>KJ</given-names></name><name><surname>Price</surname><given-names>NL</given-names></name><name><surname>Jamieson</surname><given-names>HA</given-names></name><name><surname>Lerin</surname><given-names>C</given-names></name><name><surname>Kalra</surname><given-names>A</given-names></name><name><surname>Prabhu</surname><given-names>VV</given-names></name><name><surname>Allard</surname><given-names>JS</given-names></name><name><surname>Lopez-Lluch</surname><given-names>G</given-names></name><name><surname>Lewis</surname><given-names>K</given-names></name><name><surname>Pistell</surname><given-names>PJ</given-names></name><name><surname>Poosala</surname><given-names>S</given-names></name><name><surname>Becker</surname><given-names>KG</given-names></name><name><surname>Boss</surname><given-names>O</given-names></name><name><surname>Gwinn</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Ramaswamy</surname><given-names>S</given-names></name><name><surname>Fishbein</surname><given-names>KW</given-names></name><name><surname>Spencer</surname><given-names>RG</given-names></name><name><surname>Lakatta</surname><given-names>EG</given-names></name><name><surname>Le Couteur</surname><given-names>D</given-names></name><name><surname>Shaw</surname><given-names>RJ</given-names></name><name><surname>Navas</surname><given-names>P</given-names></name><name><surname>Puigserver</surname><given-names>P</given-names></name><name><surname>Ingram</surname><given-names>DK</given-names></name><name><surname>de Cabo</surname><given-names>R</given-names></name><name><surname>Sinclair</surname><given-names>DA</given-names></name></person-group>. <article-title>Resveratrol improves health and survival of mice on a high-calorie diet</article-title>. <source>Nature</source> <year>2006</year>;<volume>444</volume>:<fpage>337</fpage>–<lpage>42</lpage></citation></ref>
<ref id="bibr44-1535370212473704"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Um</surname><given-names>JH</given-names></name><name><surname>Park</surname><given-names>SJ</given-names></name><name><surname>Kang</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Foretz</surname><given-names>M</given-names></name><name><surname>McBurney</surname><given-names>MW</given-names></name><name><surname>Kim</surname><given-names>MK</given-names></name><name><surname>Viollet</surname><given-names>B</given-names></name><name><surname>Chung</surname><given-names>JH</given-names></name></person-group>. <article-title>AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol</article-title>. <source>Diabetes</source> <year>2010</year>;<volume>59</volume>:<fpage>554</fpage>–<lpage>63</lpage></citation></ref>
<ref id="bibr45-1535370212473704"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cottart</surname><given-names>CH</given-names></name><name><surname>Nivet-Antoine</surname><given-names>V</given-names></name><name><surname>Laguillier-Morizot</surname><given-names>C</given-names></name><name><surname>Beaudeux</surname><given-names>JL</given-names></name></person-group>. <article-title>Resveratrol bioavailability and toxicity in humans</article-title>. <source>Mol Nutr Food Res</source> <year>2010</year>;<volume>54</volume>:<fpage>7</fpage>–<lpage>16</lpage></citation></ref>
<ref id="bibr46-1535370212473704"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Walle</surname><given-names>T</given-names></name><name><surname>Hsieh</surname><given-names>F</given-names></name><name><surname>DeLegge</surname><given-names>MH</given-names></name><name><surname>Oatis</surname><given-names>JE</given-names><suffix>Jr</suffix></name><name><surname>Walle</surname><given-names>UK</given-names></name></person-group>. <article-title>High absorption but very low bioavailability of oral resveratrol in humans</article-title>. <source>Drug Metab Dispos</source> <year>2004</year>;<volume>32</volume>:<fpage>1377</fpage>–<lpage>82</lpage></citation></ref>
<ref id="bibr47-1535370212473704"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vaz-da-Silva</surname><given-names>M</given-names></name><name><surname>Loureiro</surname><given-names>AI</given-names></name><name><surname>Falcao</surname><given-names>A</given-names></name><name><surname>Nunes</surname><given-names>T</given-names></name><name><surname>Rocha</surname><given-names>JF</given-names></name><name><surname>Fernandes-Lopes</surname><given-names>C</given-names></name><name><surname>Soares</surname><given-names>E</given-names></name><name><surname>Wright</surname><given-names>L</given-names></name><name><surname>Almeida</surname><given-names>L</given-names></name><name><surname>Soares-da-Silva</surname><given-names>P</given-names></name></person-group>. <article-title>Effect of food on the pharmacokinetic profile of trans-resveratrol</article-title>. <source>Int J Clin Pharmacol Ther</source> <year>2008</year>;<volume>46</volume>:<fpage>564</fpage>–<lpage>70</lpage></citation></ref>
<ref id="bibr48-1535370212473704"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Howells</surname><given-names>LM</given-names></name><name><surname>Berry</surname><given-names>DP</given-names></name><name><surname>Elliott</surname><given-names>PJ</given-names></name><name><surname>Jacobson</surname><given-names>EW</given-names></name><name><surname>Hoffmann</surname><given-names>E</given-names></name><name><surname>Hegarty</surname><given-names>B</given-names></name><name><surname>Brown</surname><given-names>K</given-names></name><name><surname>Steward</surname><given-names>WP</given-names></name><name><surname>Gescher</surname><given-names>AJ</given-names></name></person-group>. <article-title>Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases – safety, pharmacokinetics, and pharmacodynamics</article-title>. <source>Cancer Prevention Res</source> <year>2011</year>;<volume>4</volume>:<fpage>1419</fpage>–<lpage>25</lpage></citation></ref>
<ref id="bibr49-1535370212473704"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Narayanan</surname><given-names>NK</given-names></name><name><surname>Nargi</surname><given-names>D</given-names></name><name><surname>Randolph</surname><given-names>C</given-names></name><name><surname>Narayanan</surname><given-names>BA</given-names></name></person-group>. <article-title>Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice</article-title>. <source>Int J Cancer</source> <year>2009</year>;<volume>125</volume>:<fpage>1</fpage>–<lpage>8</lpage></citation></ref>
<ref id="bibr50-1535370212473704"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>JJ</given-names></name><name><surname>Nihal</surname><given-names>M</given-names></name><name><surname>Siddiqui</surname><given-names>IA</given-names></name><name><surname>Scarlett</surname><given-names>CO</given-names></name><name><surname>Bailey</surname><given-names>HH</given-names></name><name><surname>Mukhtar</surname><given-names>H</given-names></name><name><surname>Ahmad</surname><given-names>N</given-names></name></person-group>. <article-title>Enhancing the bioavailability of resveratrol by combining it with piperine</article-title>. <source>Mol Nutr Food Res</source> <year>2011</year>;<volume>55</volume>:<fpage>1169</fpage>–<lpage>76</lpage></citation></ref>
<ref id="bibr51-1535370212473704"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>KR</given-names></name><name><surname>Scott</surname><given-names>E</given-names></name><name><surname>Brown</surname><given-names>VA</given-names></name><name><surname>Gescher</surname><given-names>AJ</given-names></name><name><surname>Steward</surname><given-names>WP</given-names></name><name><surname>Brown</surname><given-names>K</given-names></name></person-group>. <article-title>Clinical trials of resveratrol</article-title>. <source>Ann NY Acad Sci</source> <year>2011</year>;<volume>1215</volume>:<fpage>161</fpage>–<lpage>69</lpage></citation></ref>
<ref id="bibr52-1535370212473704"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smoliga</surname><given-names>JM</given-names></name><name><surname>Baur</surname><given-names>JA</given-names></name><name><surname>Hausenblas</surname><given-names>HA</given-names></name></person-group>. <article-title>Resveratrol and health – a comprehensive review of human clinical trials</article-title>. <source>Mol Nutr Food Res</source> <year>2011</year>;<volume>55</volume>:<fpage>1129</fpage>–<lpage>41</lpage></citation></ref>
<ref id="bibr53-1535370212473704"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fujitaka</surname><given-names>K</given-names></name><name><surname>Otani</surname><given-names>H</given-names></name><name><surname>Jo</surname><given-names>F</given-names></name><name><surname>Jo</surname><given-names>H</given-names></name><name><surname>Nomura</surname><given-names>E</given-names></name><name><surname>Iwasaki</surname><given-names>M</given-names></name><name><surname>Nishikawa</surname><given-names>M</given-names></name><name><surname>Iwasaka</surname><given-names>T</given-names></name><name><surname>Das</surname><given-names>DK</given-names></name></person-group>. <article-title>Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment</article-title>. <source>Nutr Res</source> <year>2011</year>;<volume>31</volume>:<fpage>842</fpage>–<lpage>47</lpage></citation></ref>
<ref id="bibr54-1535370212473704"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Ungvari</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name></person-group>. <article-title>Resveratrol improves endothelial function: role of TNF-α and vascular oxidative stress</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>2009</year>;<volume>29</volume>:<fpage>1164</fpage>–<lpage>71</lpage></citation></ref>
<ref id="bibr55-1535370212473704"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Penumathsa</surname><given-names>SV</given-names></name><name><surname>Thirunavukkarasu</surname><given-names>M</given-names></name><name><surname>Zhan</surname><given-names>L</given-names></name><name><surname>Maulik</surname><given-names>G</given-names></name><name><surname>Menon</surname><given-names>VP</given-names></name><name><surname>Bagchi</surname><given-names>D</given-names></name><name><surname>Maulik</surname><given-names>N</given-names></name></person-group>. <article-title>Resveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/Akt/eNOS signalling pathway in diabetic myocardium</article-title>. <source>J Cell Mol Med</source> <year>2008</year>;<volume>12</volume>:<fpage>2350</fpage>–<lpage>61</lpage></citation></ref>
<ref id="bibr56-1535370212473704"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herrera</surname><given-names>E</given-names></name><name><surname>Ortega-Senovilla</surname><given-names>H</given-names></name></person-group>. <article-title>Disturbances in lipid metabolism in diabetic pregnancy – Are these the cause of the problem?</article-title> <source>Best Pract Res Clin Endocrinol Metab</source> <year>2010</year>;<volume>24</volume>:<fpage>515</fpage>–<lpage>25</lpage></citation></ref>
<ref id="bibr57-1535370212473704"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>IJ</given-names></name><name><surname>Ahn</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Choi</surname><given-names>MS</given-names></name><name><surname>Ha</surname><given-names>TY</given-names></name></person-group>. <article-title>Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters</article-title>. <source>Biochem Biophys Res Commun</source> <year>2008</year>;<volume>367</volume>:<fpage>190</fpage>–<lpage>94</lpage></citation></ref>
<ref id="bibr58-1535370212473704"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ofori</surname><given-names>B</given-names></name><name><surname>Rey</surname><given-names>E</given-names></name><name><surname>Berard</surname><given-names>A</given-names></name></person-group>. <article-title>Risk of congenital anomalies in pregnant users of statin drugs</article-title>. <source>Br J Clin Pharmacol</source> <year>2007</year>;<volume>64</volume>:<fpage>496</fpage>–<lpage>509</lpage></citation></ref>
<ref id="bibr59-1535370212473704"><label>59</label><citation citation-type="journal"><article-title>Statins: beware during pregnancy</article-title>. <source>Prescrire Int</source> <year>2006</year>;<volume>15</volume>:<fpage>18</fpage>–<lpage>19</lpage></citation></ref>
<ref id="bibr60-1535370212473704"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>JY</given-names></name><name><surname>Hsieh</surname><given-names>PS</given-names></name><name><surname>Huang</surname><given-names>JP</given-names></name><name><surname>Lu</surname><given-names>LS</given-names></name><name><surname>Hung</surname><given-names>LM</given-names></name></person-group>. <article-title>Activation of estrogen receptor is crucial for resveratrol-stimulating muscular glucose uptake via both insulin-dependent and -independent pathways</article-title>. <source>Diabetes</source> <year>2008</year>;<volume>57</volume>:<fpage>1814</fpage>–<lpage>23</lpage></citation></ref>
<ref id="bibr61-1535370212473704"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shearer</surname><given-names>GC</given-names></name><name><surname>Joles</surname><given-names>JA</given-names></name><name><surname>Jones</surname><given-names>H</given-names></name><name><surname>Walzem</surname><given-names>RL</given-names></name><name><surname>Kaysen</surname><given-names>GA</given-names></name></person-group>. <article-title>Estrogen effects on triglyceride metabolism in analbuminemic rats</article-title>. <source>Kidney Int</source> <year>2000</year>;<volume>57</volume>:<fpage>2268</fpage>–<lpage>74</lpage></citation></ref>
<ref id="bibr62-1535370212473704"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Basly</surname><given-names>JP</given-names></name><name><surname>Marre-Fournier</surname><given-names>F</given-names></name><name><surname>Le Bail</surname><given-names>JC</given-names></name><name><surname>Habrioux</surname><given-names>G</given-names></name><name><surname>Chulia</surname><given-names>AJ</given-names></name></person-group>. <article-title>Estrogenic/antiestrogenic and scavenging properties of (E)- and (Z)-resveratrol</article-title>. <source>Life Sci</source> <year>2000</year>;<volume>66</volume>:<fpage>769</fpage>–<lpage>77</lpage></citation></ref>
<ref id="bibr63-1535370212473704"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gehm</surname><given-names>BD</given-names></name><name><surname>McAndrews</surname><given-names>JM</given-names></name><name><surname>Chien</surname><given-names>PY</given-names></name><name><surname>Jameson</surname><given-names>JL</given-names></name></person-group>. <article-title>Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor</article-title>. <source>Proc Natl Acad Sci USA</source> <year>1997</year>;<volume>94</volume>:<fpage>14138</fpage>–<lpage>43</lpage></citation></ref>
<ref id="bibr64-1535370212473704"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>JY</given-names></name><name><surname>Park</surname><given-names>D</given-names></name><name><surname>Shin</surname><given-names>S</given-names></name><name><surname>Jeon</surname><given-names>JH</given-names></name><name><surname>Choi</surname><given-names>BI</given-names></name><name><surname>Joo</surname><given-names>SS</given-names></name><name><surname>Hwang</surname><given-names>SY</given-names></name><name><surname>Nahm</surname><given-names>SS</given-names></name><name><surname>Kim</surname><given-names>YB</given-names></name></person-group>. <article-title>Antiteratogenic effect of resveratrol in mice exposed in utero to 2,3,7,8-tetrachlorodibenzo-p-dioxin</article-title>. <source>Eur J Pharmacol</source> <year>2008</year>;<volume>591</volume>:<fpage>280</fpage>–<lpage>83</lpage></citation></ref>
<ref id="bibr65-1535370212473704"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>NP</given-names></name><name><surname>Singh</surname><given-names>US</given-names></name><name><surname>Nagarkatti</surname><given-names>M</given-names></name><name><surname>Nagarkatti</surname><given-names>PS</given-names></name></person-group>. <article-title>Resveratrol (3,5,4′-trihydroxystilbene) protects pregnant mother and fetus from the immunotoxic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin</article-title>. <source>Mol Nutr Food Res</source> <year>2011</year>;<volume>55</volume>:<fpage>209</fpage>–<lpage>19</lpage></citation></ref>
<ref id="bibr66-1535370212473704"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>LD</given-names></name><name><surname>Burdock</surname><given-names>GA</given-names></name><name><surname>Edwards</surname><given-names>JA</given-names></name><name><surname>Beck</surname><given-names>M</given-names></name><name><surname>Bausch</surname><given-names>J</given-names></name></person-group>. <article-title>Safety studies conducted on high-purity trans-resveratrol in experimental animals</article-title>. <source>Food Chem Toxicol</source> <year>2009</year>;<volume>47</volume>:<fpage>2170</fpage>–<lpage>82</lpage></citation></ref>
<ref id="bibr67-1535370212473704"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>KR</given-names></name><name><surname>Brown</surname><given-names>VA</given-names></name><name><surname>Jones</surname><given-names>DJ</given-names></name><name><surname>Britton</surname><given-names>RG</given-names></name><name><surname>Hemingway</surname><given-names>D</given-names></name><name><surname>Miller</surname><given-names>AS</given-names></name><name><surname>West</surname><given-names>KP</given-names></name><name><surname>Booth</surname><given-names>TD</given-names></name><name><surname>Perloff</surname><given-names>M</given-names></name><name><surname>Crowell</surname><given-names>JA</given-names></name><name><surname>Brenner</surname><given-names>DE</given-names></name><name><surname>Steward</surname><given-names>WP</given-names></name><name><surname>Gescher</surname><given-names>AJ</given-names></name><name><surname>Brown</surname><given-names>K</given-names></name></person-group>. <article-title>Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients</article-title>. <source>Cancer Res</source> <year>2010</year>;<volume>70</volume>:<fpage>7392</fpage>–<lpage>99</lpage></citation></ref>
<ref id="bibr68-1535370212473704"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>CK</given-names></name><name><surname>LaVoie</surname><given-names>HA</given-names></name><name><surname>Dipette</surname><given-names>DJ</given-names></name><name><surname>Singh</surname><given-names>US</given-names></name></person-group>. <article-title>Resveratrol restores Nrf2 level and prevents ethanol-induced toxic effects in the cerebellum of a rodent model of fetal alcohol spectrum disorders</article-title>. <source>Mol Pharmacol</source> <year>2011</year>;<volume>80</volume>:<fpage>446</fpage>–<lpage>57</lpage></citation></ref>
<ref id="bibr69-1535370212473704"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>GL</given-names></name><name><surname>Norgard</surname><given-names>B</given-names></name><name><surname>Puho</surname><given-names>E</given-names></name><name><surname>Rothman</surname><given-names>KJ</given-names></name><name><surname>Sorensen</surname><given-names>HT</given-names></name><name><surname>Czeizel</surname><given-names>AE</given-names></name></person-group>. <article-title>Risk of specific congenital abnormalities in offspring of women with diabetes</article-title>. <source>Diabet Med</source> <year>2005</year>;<volume>22</volume>:<fpage>693</fpage>–<lpage>96</lpage></citation></ref>
<ref id="bibr70-1535370212473704"><label>70</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reece</surname><given-names>EA</given-names></name><name><surname>Wu</surname><given-names>YK</given-names></name></person-group>. <article-title>Prevention of diabetic embryopathy in offspring of diabetic rats with use of a cocktail of deficient substrates and an antioxidant</article-title>. <source>Am J Obstet Gynecol</source> <year>1997</year>;<volume>176</volume>:<fpage>790</fpage>–<lpage>97</lpage></citation></ref>
<ref id="bibr71-1535370212473704"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zabihi</surname><given-names>S</given-names></name><name><surname>Wentzel</surname><given-names>P</given-names></name><name><surname>Eriksson</surname><given-names>UJ</given-names></name></person-group>. <article-title>Altered uterine perfusion is involved in fetal outcome of diabetic rats</article-title>. <source>Placenta</source> <year>2008</year>;<volume>29</volume>:<fpage>413</fpage>–<lpage>21</lpage></citation></ref>
<ref id="bibr72-1535370212473704"><label>72</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Rottinghaus</surname><given-names>GE</given-names></name><name><surname>Simonyi</surname><given-names>A</given-names></name><name><surname>Lubahn</surname><given-names>D</given-names></name><name><surname>Sun</surname><given-names>GY</given-names></name><name><surname>Sun</surname><given-names>AY</given-names></name></person-group>. <article-title>Resveratrol protects against global cerebral ischemic injury in gerbils</article-title>. <source>Brain Res</source> <year>2002</year>;<volume>958</volume>:<fpage>439</fpage>–<lpage>47</lpage></citation></ref>
<ref id="bibr73-1535370212473704"><label>73</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mokni</surname><given-names>M</given-names></name><name><surname>Elkahoui</surname><given-names>S</given-names></name><name><surname>Limam</surname><given-names>F</given-names></name><name><surname>Amri</surname><given-names>M</given-names></name><name><surname>Aouani</surname><given-names>E</given-names></name></person-group>. <article-title>Effect of resveratrol on antioxidant enzyme activities in the brain of healthy rat</article-title>. <source>Neurochem Res</source> <year>2007</year>;<volume>32</volume>:<fpage>981</fpage>–<lpage>87</lpage></citation></ref>
<ref id="bibr74-1535370212473704"><label>74</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ates</surname><given-names>O</given-names></name><name><surname>Cayli</surname><given-names>SR</given-names></name><name><surname>Yucel</surname><given-names>N</given-names></name><name><surname>Altinoz</surname><given-names>E</given-names></name><name><surname>Kocak</surname><given-names>A</given-names></name><name><surname>Durak</surname><given-names>MA</given-names></name><name><surname>Turkoz</surname><given-names>Y</given-names></name><name><surname>Yologlu</surname><given-names>S</given-names></name></person-group>. <article-title>Central nervous system protection by resveratrol in streptozotocin-induced diabetic rats</article-title>. <source>J Clin Neurosci</source> <year>2007</year>;<volume>14</volume>:<fpage>256</fpage>–<lpage>60</lpage></citation></ref>
<ref id="bibr75-1535370212473704"><label>75</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Venturini</surname><given-names>CD</given-names></name><name><surname>Merlo</surname><given-names>S</given-names></name><name><surname>Souto</surname><given-names>AA</given-names></name><name><surname>Fernandes Mda</surname><given-names>C</given-names></name><name><surname>Gomez</surname><given-names>R</given-names></name><name><surname>Rhoden</surname><given-names>CR</given-names></name></person-group>. <article-title>Resveratrol and red wine function as antioxidants in the nervous system without cellular proliferative effects during experimental diabetes</article-title>. <source>Oxid Med Cell Longev</source> <year>2010</year>;<volume>3</volume>:<fpage>434</fpage>–<lpage>41</lpage></citation></ref>
<ref id="bibr76-1535370212473704"><label>76</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kruman</surname><given-names>I</given-names></name><name><surname>Bruce-Keller</surname><given-names>AJ</given-names></name><name><surname>Bredesen</surname><given-names>D</given-names></name><name><surname>Waeg</surname><given-names>G</given-names></name><name><surname>Mattson</surname><given-names>MP</given-names></name></person-group>. <article-title>Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis</article-title>. <source>J Neurosci</source> <year>1997</year>;<volume>17</volume>:<fpage>5089</fpage>–<lpage>100</lpage></citation></ref>
<ref id="bibr77-1535370212473704"><label>77</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ong</surname><given-names>WY</given-names></name><name><surname>Lu</surname><given-names>XR</given-names></name><name><surname>Hu</surname><given-names>CY</given-names></name><name><surname>Halliwell</surname><given-names>B</given-names></name></person-group>. <article-title>Distribution of hydroxynonenal-modified proteins in the kainate-lesioned rat hippocampus: evidence that hydroxynonenal formation precedes neuronal cell death</article-title>. <source>Free Radic Biol Med</source> <year>2000</year>;<volume>28</volume>:<fpage>1214</fpage>–<lpage>21</lpage></citation></ref>
<ref id="bibr78-1535370212473704"><label>78</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Etienne-Manneville</surname><given-names>S</given-names></name><name><surname>Hall</surname><given-names>A</given-names></name></person-group>. <article-title>Rho GTPases in cell biology</article-title>. <source>Nature</source> <year>2002</year>;<volume>420</volume>:<fpage>629</fpage>–<lpage>35</lpage></citation></ref>
<ref id="bibr79-1535370212473704"><label>79</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>US</given-names></name><name><surname>Kunar</surname><given-names>MT</given-names></name><name><surname>Kao</surname><given-names>YL</given-names></name><name><surname>Baker</surname><given-names>KM</given-names></name></person-group>. <article-title>Role of transglutaminase II in retinoic acid-induced activation of RhoA- associated kinase-2</article-title>. <source>Embo J</source> <year>2001</year>;<volume>20</volume>:<fpage>2413</fpage>–<lpage>23</lpage></citation></ref>
<ref id="bibr80-1535370212473704"><label>80</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>US</given-names></name><name><surname>Pan</surname><given-names>J</given-names></name><name><surname>Kao</surname><given-names>YL</given-names></name><name><surname>Joshi</surname><given-names>S</given-names></name><name><surname>Young</surname><given-names>KL</given-names></name><name><surname>Baker</surname><given-names>KM</given-names></name></person-group>. <article-title>Tissue transglutaminase mediates activation of RhoA and MAP kinase pathways during retinoic acid-induced neuronal differentiation of SH-SY5Y cells</article-title>. <source>J Biol Chem</source> <year>2003</year>;<volume>278</volume>:<fpage>391</fpage>–<lpage>99</lpage></citation></ref>
<ref id="bibr81-1535370212473704"><label>81</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nobes</surname><given-names>CD</given-names></name><name><surname>Hawkins</surname><given-names>P</given-names></name><name><surname>Stephens</surname><given-names>L</given-names></name><name><surname>Hall</surname><given-names>A</given-names></name></person-group>. <article-title>Activation of the small GTP-binding proteins rho and rac by growth factor receptors</article-title>. <source>J Cell Sci</source> <year>1995</year>;<volume>108</volume>(Part 1):<fpage>225</fpage>–<lpage>33</lpage></citation></ref>
<ref id="bibr82-1535370212473704"><label>82</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>J</given-names></name><name><surname>Kao</surname><given-names>YL</given-names></name><name><surname>Joshi</surname><given-names>S</given-names></name><name><surname>Jeetendran</surname><given-names>S</given-names></name><name><surname>Dipette</surname><given-names>D</given-names></name><name><surname>Singh</surname><given-names>US</given-names></name></person-group>. <article-title>Activation of Rac1 by phosphatidylinositol 3-kinase in vivo: role in activation of mitogen-activated protein kinase (MAPK) pathways and retinoic acid-induced neuronal differentiation of SH-SY5Y cells</article-title>. <source>J Neurochem</source> <year>2005</year>;<volume>93</volume>:<fpage>571</fpage>–<lpage>83</lpage></citation></ref>
<ref id="bibr83-1535370212473704"><label>83</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scita</surname><given-names>G</given-names></name><name><surname>Tenca</surname><given-names>P</given-names></name><name><surname>Frittoli</surname><given-names>E</given-names></name><name><surname>Tocchetti</surname><given-names>A</given-names></name><name><surname>Innocenti</surname><given-names>M</given-names></name><name><surname>Giardina</surname><given-names>G</given-names></name><name><surname>Di Fiore</surname><given-names>PP</given-names></name></person-group>. <article-title>Signaling from Ras to Rac and beyond: not just a matter of GEFs</article-title>. <source>EMBO J</source> <year>2000</year>;<volume>19</volume>:<fpage>2393</fpage>–<lpage>98</lpage></citation></ref>
<ref id="bibr84-1535370212473704"><label>84</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sprang</surname><given-names>SR</given-names></name></person-group>. <article-title>G proteins, effectors and GAPs: structure and mechanism</article-title>. <source>Curr Opin Struct Biol</source> <year>1997</year>;<volume>7</volume>:<fpage>849</fpage>–<lpage>56</lpage></citation></ref>
<ref id="bibr85-1535370212473704"><label>85</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname><given-names>MJ</given-names></name><name><surname>Maru</surname><given-names>Y</given-names></name><name><surname>Leonard</surname><given-names>D</given-names></name><name><surname>Witte</surname><given-names>ON</given-names></name><name><surname>Evans</surname><given-names>T</given-names></name><name><surname>Cerione</surname><given-names>RA</given-names></name></person-group>. <article-title>A GDP dissociation inhibitor that serves as a GTPase inhibitor for the Ras-like protein CDC42Hs</article-title>. <source>Science</source> <year>1992</year>;<volume>258</volume>:<fpage>812</fpage>–<lpage>15</lpage></citation></ref>
<ref id="bibr86-1535370212473704"><label>86</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brouns</surname><given-names>MR</given-names></name><name><surname>Matheson</surname><given-names>SF</given-names></name><name><surname>Hu</surname><given-names>KQ</given-names></name><name><surname>Delalle</surname><given-names>I</given-names></name><name><surname>Caviness</surname><given-names>VS</given-names></name><name><surname>Silver</surname><given-names>J</given-names></name><name><surname>Bronson</surname><given-names>RT</given-names></name><name><surname>Settleman</surname><given-names>J</given-names></name></person-group>. <article-title>The adhesion signaling molecule p190 RhoGAP is required for morphogenetic processes in neural development</article-title>. <source>Development</source> <year>2000</year>;<volume>127</volume>:<fpage>4891</fpage>–<lpage>903</lpage></citation></ref>
<ref id="bibr87-1535370212473704"><label>87</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ybot-Gonzalez</surname><given-names>P</given-names></name><name><surname>Savery</surname><given-names>D</given-names></name><name><surname>Gerrelli</surname><given-names>D</given-names></name><name><surname>Signore</surname><given-names>M</given-names></name><name><surname>Mitchell</surname><given-names>CE</given-names></name><name><surname>Faux</surname><given-names>CH</given-names></name><name><surname>Greene</surname><given-names>ND</given-names></name><name><surname>Copp</surname><given-names>AJ</given-names></name></person-group>. <article-title>Convergent extension, planar-cell-polarity signalling and initiation of mouse neural tube closure</article-title>. <source>Development</source> <year>2007</year>;<volume>134</volume>:<fpage>789</fpage>–<lpage>99</lpage></citation></ref>
<ref id="bibr88-1535370212473704"><label>88</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lindqvist</surname><given-names>M</given-names></name><name><surname>Horn</surname><given-names>Z</given-names></name><name><surname>Bryja</surname><given-names>V</given-names></name><name><surname>Schulte</surname><given-names>G</given-names></name><name><surname>Papachristou</surname><given-names>P</given-names></name><name><surname>Ajima</surname><given-names>R</given-names></name><name><surname>Dyberg</surname><given-names>C</given-names></name><name><surname>Arenas</surname><given-names>E</given-names></name><name><surname>Yamaguchi</surname><given-names>TP</given-names></name><name><surname>Lagercrantz</surname><given-names>H</given-names></name><name><surname>Ringstedt</surname><given-names>T</given-names></name></person-group>. <article-title>Vang-like protein 2 and Rac1 interact to regulate adherens junctions</article-title>. <source>J Cell Sci</source> <year>2010</year>;<volume>123</volume>:<fpage>472</fpage>–<lpage>83</lpage></citation></ref>
<ref id="bibr89-1535370212473704"><label>89</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Morita</surname><given-names>H</given-names></name><name><surname>Ueno</surname><given-names>N</given-names></name></person-group>. <article-title>Molecular mechanisms of cell shape changes that contribute to vertebrate neural tube closure</article-title>. <source>Dev Growth Differ</source> <year>2012</year>;<volume>54</volume>:<fpage>266</fpage>–<lpage>76</lpage></citation></ref>
<ref id="bibr90-1535370212473704"><label>90</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kinoshita</surname><given-names>N</given-names></name><name><surname>Sasai</surname><given-names>N</given-names></name><name><surname>Misaki</surname><given-names>K</given-names></name><name><surname>Yonemura</surname><given-names>S</given-names></name></person-group>. <article-title>Apical accumulation of Rho in the neural plate is important for neural plate cell shape change and neural tube formation</article-title>. <source>Mol Biol Cell</source> <year>2008</year>;<volume>19</volume>:<fpage>2289</fpage>–<lpage>99</lpage></citation></ref>
<ref id="bibr91-1535370212473704"><label>91</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Camerer</surname><given-names>E</given-names></name><name><surname>Barker</surname><given-names>A</given-names></name><name><surname>Duong</surname><given-names>DN</given-names></name><name><surname>Ganesan</surname><given-names>R</given-names></name><name><surname>Kataoka</surname><given-names>H</given-names></name><name><surname>Cornelissen</surname><given-names>I</given-names></name><name><surname>Darragh</surname><given-names>MR</given-names></name><name><surname>Hussain</surname><given-names>A</given-names></name><name><surname>Zheng</surname><given-names>YW</given-names></name><name><surname>Srinivasan</surname><given-names>Y</given-names></name><name><surname>Brown</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>SM</given-names></name><name><surname>Regard</surname><given-names>JB</given-names></name><name><surname>Lin</surname><given-names>CY</given-names></name><name><surname>Craik</surname><given-names>CS</given-names></name><name><surname>Kirchhofer</surname><given-names>D</given-names></name><name><surname>Coughlin</surname><given-names>SR</given-names></name></person-group>. <article-title>Local protease signaling contributes to neural tube closure in the mouse embryo</article-title>. <source>Dev Cell</source> <year>2010</year>;<volume>18</volume>:<fpage>25</fpage>–<lpage>38</lpage></citation></ref>
<ref id="bibr92-1535370212473704"><label>92</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jalink</surname><given-names>K</given-names></name><name><surname>van Corven</surname><given-names>EJ</given-names></name><name><surname>Hengeveld</surname><given-names>T</given-names></name><name><surname>Morii</surname><given-names>N</given-names></name><name><surname>Narumiya</surname><given-names>S</given-names></name><name><surname>Moolenaar</surname><given-names>WH</given-names></name></person-group>. <article-title>Inhibition of lysophosphatidate- and thrombin-induced neurite retraction and neuronal cell rounding by ADP ribosylation of the small GTP-binding protein Rho</article-title>. <source>J Cell Biol</source> <year>1994</year>;<volume>126</volume>:<fpage>801</fpage>–<lpage>10</lpage></citation></ref>
<ref id="bibr93-1535370212473704"><label>93</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kozma</surname><given-names>R</given-names></name><name><surname>Sarner</surname><given-names>S</given-names></name><name><surname>Ahmed</surname><given-names>S</given-names></name><name><surname>Lim</surname><given-names>L</given-names></name></person-group>. <article-title>Rho family GTPases and neuronal growth cone remodelling: relationship between increased complexity induced by Cdc42Hs, Rac1, and acetylcholine and collapse induced by RhoA and lysophosphatidic acid</article-title>. <source>Mol Cell Biol</source> <year>1997</year>;<volume>17</volume>:<fpage>1201</fpage>–<lpage>11</lpage></citation></ref>
<ref id="bibr94-1535370212473704"><label>94</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leeuwen</surname><given-names>FN</given-names></name><name><surname>Kain</surname><given-names>HE</given-names></name><name><surname>Kammen</surname><given-names>RA</given-names></name><name><surname>Michiels</surname><given-names>F</given-names></name><name><surname>Kranenburg</surname><given-names>OW</given-names></name><name><surname>Collard</surname><given-names>JG</given-names></name></person-group>. <article-title>The guanine nucleotide exchange factor Tiam1 affects neuronal morphology; opposing roles for the small GTPases Rac and Rho</article-title>. <source>J Cell Biol</source> <year>1997</year>;<volume>139</volume>:<fpage>797</fpage>–<lpage>807</lpage></citation></ref>
<ref id="bibr95-1535370212473704"><label>95</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fukazawa</surname><given-names>Y</given-names></name><name><surname>Saitoh</surname><given-names>Y</given-names></name><name><surname>Ozawa</surname><given-names>F</given-names></name><name><surname>Ohta</surname><given-names>Y</given-names></name><name><surname>Mizuno</surname><given-names>K</given-names></name><name><surname>Inokuchi</surname><given-names>K</given-names></name></person-group>. <article-title>Hippocampal LTP is accompanied by enhanced F-actin content within the dendritic spine that is essential for late LTP maintenance <italic>in vivo</italic></article-title>. <source>Neuron</source> <year>2003</year>;<volume>38</volume>:<fpage>447</fpage>–<lpage>60</lpage></citation></ref>
<ref id="bibr96-1535370212473704"><label>96</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zito</surname><given-names>K</given-names></name><name><surname>Knott</surname><given-names>G</given-names></name><name><surname>Shepherd</surname><given-names>GM</given-names></name><name><surname>Shenolikar</surname><given-names>S</given-names></name><name><surname>Svoboda</surname><given-names>K</given-names></name></person-group>. <article-title>Induction of spine growth and synapse formation by regulation of the spine actin cytoskeleton</article-title>. <source>Neuron</source> <year>2004</year>;<volume>44</volume>:<fpage>321</fpage>–<lpage>34</lpage></citation></ref>
<ref id="bibr97-1535370212473704"><label>97</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>L</given-names></name></person-group>. <article-title>Rho GTPases in neuronal morphogenesis</article-title>. <source>Nat Rev Neurosci</source> <year>2000</year>;<volume>1</volume>:<fpage>173</fpage>–<lpage>80</lpage></citation></ref>
<ref id="bibr98-1535370212473704"><label>98</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>L</given-names></name></person-group>. <article-title>Actin cytoskeleton regulation in neuronal morphogenesis and structural plasticity</article-title>. <source>Annu Rev Cell Dev Biol</source> <year>2002</year>;<volume>18</volume>:<fpage>601</fpage>–<lpage>35</lpage></citation></ref>
<ref id="bibr99-1535370212473704"><label>99</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diana</surname><given-names>G</given-names></name><name><surname>Valentini</surname><given-names>G</given-names></name><name><surname>Travaglione</surname><given-names>S</given-names></name><name><surname>Falzano</surname><given-names>L</given-names></name><name><surname>Pieri</surname><given-names>M</given-names></name><name><surname>Zona</surname><given-names>C</given-names></name><name><surname>Meschini</surname><given-names>S</given-names></name><name><surname>Fabbri</surname><given-names>A</given-names></name><name><surname>Fiorentini</surname><given-names>C</given-names></name></person-group>. <article-title>Enhancement of learning and memory after activation of cerebral Rho GTPases</article-title>. <source>Proc Natl Acad Sci USA</source> <year>2007</year>;<volume>104</volume>:<fpage>636</fpage>–<lpage>41</lpage></citation></ref>
<ref id="bibr100-1535370212473704"><label>100</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramakers</surname><given-names>GJ</given-names></name></person-group>. <article-title>Rho proteins, mental retardation and the cellular basis of cognition</article-title>. <source>Trends Neurosci</source> <year>2002</year>;<volume>25</volume>:<fpage>191</fpage>–<lpage>99</lpage></citation></ref>
<ref id="bibr101-1535370212473704"><label>101</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sin</surname><given-names>WC</given-names></name><name><surname>Chen</surname><given-names>XQ</given-names></name><name><surname>Leung</surname><given-names>T</given-names></name><name><surname>Lim</surname><given-names>L</given-names></name></person-group>. <article-title>RhoA-binding kinase alpha translocation is facilitated by the collapse of the vimentin intermediate filament network</article-title>. <source>Mol Cell Biol</source> <year>1998</year>;<volume>18</volume>:<fpage>6325</fpage>–<lpage>39</lpage></citation></ref>
<ref id="bibr102-1535370212473704"><label>102</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aghajanian</surname><given-names>A</given-names></name><name><surname>Wittchen</surname><given-names>ES</given-names></name><name><surname>Campbell</surname><given-names>SL</given-names></name><name><surname>Burridge</surname><given-names>K</given-names></name></person-group>. <article-title>Direct activation of RhoA by reactive oxygen species requires a redox-sensitive motif</article-title>. <source>PLoS One</source> <year>2009</year>;<volume>4</volume>:<fpage>e8045</fpage></citation></ref>
<ref id="bibr103-1535370212473704"><label>103</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kondrikov</surname><given-names>D</given-names></name><name><surname>Caldwell</surname><given-names>RB</given-names></name><name><surname>Dong</surname><given-names>Z</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name></person-group>. <article-title>Reactive oxygen species-dependent RhoA activation mediates collagen synthesis in hyperoxic lung fibrosis</article-title>. <source>Free Radic Biol Med</source> <year>2011</year>;<volume>50</volume>:<fpage>1689</fpage>–<lpage>98</lpage></citation></ref>
<ref id="bibr104-1535370212473704"><label>104</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mark</surname><given-names>M</given-names></name><name><surname>Ghyselinck</surname><given-names>NB</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name></person-group>. <article-title>Function of retinoic acid receptors during embryonic development</article-title>. <source>Nucl Recept Signal</source> <year>2009</year>;<volume>7</volume>:<fpage>e002</fpage></citation></ref>
<ref id="bibr105-1535370212473704"><label>105</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>L</given-names></name><name><surname>Gale</surname><given-names>E</given-names></name><name><surname>Maden</surname><given-names>M</given-names></name></person-group>. <article-title>The role of retinoic acid in the morphogenesis of the neural tube</article-title>. <source>J Anat</source> <year>2003</year>;<volume>203</volume>:<fpage>357</fpage>–<lpage>68</lpage></citation></ref>
<ref id="bibr106-1535370212473704"><label>106</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Yao</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Yan</surname><given-names>H</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Ying</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name></person-group>. <article-title>Suppression of retinoic acid receptors may contribute to embryonic skeleton hypoplasia in maternal rats with chronic vitamin A deficiency</article-title>. <source>J Nutr Biochem</source> <year>2010</year>;<volume>21</volume>:<fpage>710</fpage>–<lpage>16</lpage></citation></ref>
<ref id="bibr107-1535370212473704"><label>107</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>WH</given-names></name><name><surname>Morriss-Kay</surname><given-names>GM</given-names></name><name><surname>Copp</surname><given-names>AJ</given-names></name></person-group>. <article-title>Genesis and prevention of spinal neural tube defects in the curly tail mutant mouse: involvement of retinoic acid and its nuclear receptors RAR-beta and RAR-gamma</article-title>. <source>Development</source> <year>1995</year>;<volume>121</volume>:<fpage>681</fpage>–<lpage>91</lpage></citation></ref>
<ref id="bibr108-1535370212473704"><label>108</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lenhard</surname><given-names>JM</given-names></name></person-group>. <article-title>PPAR gamma/RXR as a molecular target for diabetes</article-title>. <source>Recept Channel</source> <year>2001</year>;<volume>7</volume>:<fpage>249</fpage>–<lpage>58</lpage></citation></ref>
<ref id="bibr109-1535370212473704"><label>109</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>CK</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>LaVoie</surname><given-names>HA</given-names></name><name><surname>Dipette</surname><given-names>DJ</given-names></name><name><surname>Singh</surname><given-names>US</given-names></name></person-group>. <article-title>Resveratrol prevents impairment in activation of retinoic acid receptors and MAP kinases in the embryos of a rodent model of diabetic embryopathy</article-title>. <source>Reprod Sci</source> <year>2012</year>;<volume>19</volume>:<fpage>949</fpage>–<lpage>61</lpage></citation></ref>
<ref id="bibr110-1535370212473704"><label>110</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Hales</surname><given-names>BF</given-names></name></person-group>. <article-title>p38 and c-Jun N-terminal kinase mitogen-activated protein kinase signaling pathways play distinct roles in the response of organogenesis-stage embryos to a teratogen</article-title>. <source>J Pharmacol Exp Ther</source> <year>2008</year>;<volume>326</volume>:<fpage>764</fpage>–<lpage>72</lpage></citation></ref>
<ref id="bibr111-1535370212473704"><label>111</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Torres</surname><given-names>M</given-names></name><name><surname>Forman</surname><given-names>HJ</given-names></name></person-group>. <article-title>Redox signaling and the MAP kinase pathways</article-title>. <source>Biofactors</source> <year>2003</year>;<volume>17</volume>:<fpage>287</fpage>–<lpage>96</lpage></citation></ref>
<ref id="bibr112-1535370212473704"><label>112</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malemud</surname><given-names>CJ</given-names></name></person-group>. <article-title>Inhibitors of stress-activated protein/mitogen-activated protein kinase pathways</article-title>. <source>Curr Opin Pharmacol</source> <year>2007</year>;<volume>7</volume>:<fpage>339</fpage>–<lpage>43</lpage></citation></ref></ref-list>
</back>
</article>